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3Foreword
From the JRC Director General and the EASAC President
This policy report is the result of the first strategic liaison 
between the JRC and EASAC and provides independent, 
cross-referenced, science-based analysis of the impact 
of nanomaterials on human health. Our report is direc-
ted at European and national policy-makers and citizens. 
Nanomaterials have the potential to play a major role in 
European innovation, economic growth and industrial 
competitiveness. In order to capitalise on this technolo-
gy and reap the promised benefits, the EU must ensure 
the appropriate framework for its success. A key element 
in this regard concerns a harmonised assessment of the 
safety of nanomaterials and this requires a strengthened 
dialogue between policy-makers and scientists.  
 
The joint initiative of EASAC and the JRC also contributes 
to the collective EU targets and supports integrated efforts 
for nanotechnology innovation, as well as public debate 
on the future of nanomaterials. Based on the experience 
of this initiative, and the existing synergies between the 
activities of the two organisations, a more structured coo-
peration will be developed. The cooperation will address 
other scientific topics relevant to the key priorities of the 
EU and serve to create closer links between EU national 
science academies and the policy-making processes in 
the EU. 
From the Chairs of the Expert Group
A first meeting took place in Lugano, Switzerland, on 
17th August 2009 between EASAC1 and EC-JRC2, where 
it was decided to draft a joint report on the impact of 
manufactured nanomaterials on human health. Because 
the agreed focus of the report was to be on manufactured 
nanoparticles and the legal and societal implications 
related to their potential risks and benefits, the report was 
entitled: ‘Considerations on Benefit–Risk Assessment of 
Engineered Nanomaterials’.
A representative group of 13 experts (listed in the Annex) 
across the EU was selected on to a panel to address these 
issues. The panel included expert representatives from 
both EASAC and EC-JRC. This group met for the first time 
in February 2010 in Ispra (Italy) and thereafter in Zurich 
(Switzerland) in July and in November 2010. 
 
The health and environmental effects of engineered 
(by humankind) nanomaterials are not yet clearly 
understood, although they are already used in a variety 
of applications. However, health effects of nanoparticles 
present unintentionally in the environment, for example 
deriving from combustion processes (even in a simple 
process such as lighting a candle), have been studied 
extensively, since the time of Leonardo da Vinci.
The goal of the present report is to highlight the state-
of-the-art knowledge on safety aspects of engineered 
nanomaterials and to identify needs for further scientific 
investigations. 
The exploitation potential of nanotechnology has only 
just begun to be tapped, and the associated economic 
and technological gains are likely to be considerable for 
those who are able to capitalise from the technology 
from an early point. In this regard, Europe should not be 
disadvantaged. It is the intent of this report to point to the 
ways in which Europe can best reap the promised rewards 
without compromising appropriate and due consideration 
of the necessary health and environment safeguards, 
especially concerning nanomaterials, which otherwise 
may ultimately counteract any preliminary gains. 
We wish all readers of this report a stimulating reflection on 
the primary issues pertinent to accomplishing this goal.
1 Represented by Prof. Dr. Denis Monard, President of the Swiss Academy of Sciences, and Prof. Dr. Peter Gehr, President of the Steering 
 Committee of the National Research Programme 64 ‘Opportunities and Risks of Nanomaterials’ (SC NRP 64) of the Swiss National Science Foundation.
2 Represented by Prof. Dr. Elke Anklam, Director of the Institute for Health and Consumer Protection (IHCP), and Dr. Hermann Stamm, IHCP Head of 
 Unit responsible for nanotechnology.
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5Executive Summary
Nanotechnology and its importance for Europe
Nanotechnology encompasses the design, characte-
risation, production and application of materials and 
systems by controlling shape and size at the nanoscale 
(nanometres). Nanomaterials may differ from other 
materials because of their relatively large specific surface 
area, such that surface properties become particularly 
important.
There has been rapid growth in investment in nano-
technology by both the public and private sectors 
worldwide. In the EU, nanotechnology is expected to 
become an important strategic contributor to achieving 
economic gain and societal and individual benefits. 
Although there is continuing scientific uncertainty and 
controversy about the safety of nanomaterials, there 
is only a limited amount of scientific evidence about 
nanomaterials and human health risks. 
It is important to ensure that timely policy development 
takes these issues into consideration. Uncertainty about 
safety may lead to polarised public debate and to business 
unwillingness to invest further in nanotechnology. 
A clear regulatory framework to address potential health 
and environmental impacts, within the wider context of 
evaluating and communicating the benefit–risk balance, 
must be a core part of Europe’s integrated efforts for 
nanotechnology innovation. 
Purpose of the present report
Although several studies have examined the effect 
of environmental nanoparticles, for example from 
combustion processes, on human health, there is as yet no 
generally acceptable paradigm for safety assessment of 
nanomaterials in consumer and other products. Therefore, 
a working group was established to consider issues for 
the possible impact of nanomaterials on human health 
focussing specifically on engineered nanomaterials. This 
represents the first joint initiative between EASAC and the 
JRC. The working group was given the remit to describe 
the state of the art of benefits and potential risks, current 
methods for safety assessment, and to evaluate their 
relevance, identify knowledge gaps in studying the safety 
of currently used nanomaterials, and recommend priorities 
for nanomaterial research and the regulatory framework. 
 
This report focuses on key principles and issues, cross-
referencing other sources for detailed information, rather 
than attempting a comprehensive account of the science. 
The focus is on human health although environmental 
effects are also discussed when directly relevant to human 
health.
Benefits and safety of nanomaterials
The term ‘nanotechnology’ covers a very broad range of 
entities and industrial applications. It is expected that 
many of the applications will help to improve human 
health and quality of life. The medical application of 
nanotechnology is probably one of the fastest growing 
fields, with developments in therapeutic, diagnostic and 
imaging uses (e.g. in cancer). 
Applications in food include objectives to enhance flavour 
and texture and encapsulate micronutrients to prolong 
their stability, augmented by packaging applications 
to prolong shelf life and avoid bacterial contamination. 
Potential applications in other sectors include environ-
mental remediation to detect and eliminate toxic 
substances, energy generation and storage plus multiple 
other commercial uses of novel materials. 
Several inventories of consumer nanoproducts exist, some 
containing more than 1,000 items; however, inclusion was 
based on the producer’s claim rather than a standard 
definition, and this could create challenges for a coherent 
and systematic safety assessment. The rapid increase 
in the use of nanomaterials in industry and consumer 
products is causing concerns about the potential 
effects on human health and on the environment. It is 
generally accepted that many areas of nanotechnology 
do not present new hazards so that current regulatory 
frameworks are adequate. But it is also possible that 
new forms of engineered nanomaterials may require 
existing regulations to be modified or even new specific 
regulations to cover the lifecycle of production, use and 
disposal.
We emphasise that the regulatory framework for the 
safety assessment of nanomaterials should follow 
the same principles and sector-specific requirements 
as for other products: risk is a function of hazard and 
exposure. Direct exposure depends on the intended 
application; indirect exposure arises from involvement 
in manufacturing processes and from the environment 
more generally. 
We conclude that it is essential to invest significantly in 
research for safety assessment while seeking to expedite 
regulatory review of the products emanating from that 
science.
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filling the gaps
Although there are many research projects worldwide 
assessing the potential hazards and risks, there have 
been concerns about their quality and relevance. The lack 
of standardised materials and methodologies makes it 
difficult to compare results from different researchers and 
different nanoproducts. 
Nanosafety assessment has its origins in research on 
ultra-fine dust and lung damage; the study of particle–
lung interactions remains a major research topic with 
the objective to clarify biological processes and potential 
consequences for disease. Beyond the lung, there are many 
gaps in knowledge about the health impacts that may 
occur after inhalation, in relation to uptake, distribution, 
accumulation and biological effects in secondary organs, 
although it is known, for example, that some nanoparticles 
can cross the blood–brain barrier. Other routes of entry 
that may be intended for some nanomaterial applications, 
such as oral ingestion, and in particular exposure to 
the skin and intravenous administration, are less well-
characterised. 
As a generalisation, it can be said that the same properties 
that are desirable in some applications, such as the ability 
to cross biological barriers and the manifestation of high 
surface reactivity, are also the properties that may give 
rise to toxicity (the so-called ‘nanomaterials paradox’). This 
paradox is not unique to nanomaterials or nanomedicine 
as the principle applies also to pharmaceuticals. 
Among the key issues for hazard assessment are the 
following:
Dose – testing should aim to identify potential 
hazards by establishing dose response relationships, 
over the long-term when necessary, but many 
reported studies are short-term, have used very high 
doses and their relevance to likely exposure can be 
questioned. Furthermore, dose must be quantified 
based on a detailed understanding of the physico-
chemical properties of the nanomaterial, but this was 
not always possible in the earlier studies.
Standardisation – it is critically important to use 
validated, standardised assays so that (1) results from 
different researchers can be compared and (2) assays 
in vitro or animal studies can reasonably be expected 
to predict an effect in humans. Again, this has not 
always yet been possible. 
Differences in individual susceptibility – relatively 
little progress has been made in exploring factors 
that may influence the response of individuals, 
for example ageing, genetic predisposition and 
epigenetics.
Studies at cellular level – there is still little knowledge 
about how nanoparticles interact with the cell 
membrane, how they are transported into cells, into 
lysosomes, mitochondria and the nucleus, and the 
consequences of these interactions. 
Studies at organ and system levels – among the 
priorities there is need to study toxicokinetics for 
extra-pulmonary translocation and transport after 
other routes of entry, particularly for effects on foetal 
development and cardiovascular, nervous, hepatic, 
immune and endocrine systems and organ–organ 
interplay (activation of a response to nanoparticles 
in one organ with effects elsewhere).
It is equally important to do much more in assessing 
exposure, whether intended or unintended. Few studies 
describe workplace, consumer or environmental exposure 
or relate exposure to real-life conditions. There is very little 
information on workplace exposure in smaller companies 
or lower-technology sectors downstream from the point 
of manufacture. More must be done to assess inhalation 
exposure in occupational settings where the greatest 
exposure is anticipated (and where there is the potential 
for environmental release) and to raise awareness in other 
settings. It is also important to assess exposure by other 
routes, whether or not intended for the application. One 
key issue is the choice of practical metrics to quantify 
the concentration of nanoparticles. Measurement of 
total surface area or particle number is likely to be more 
meaningful than total mass concentration. Consensus 
on methodologies is needed to construct integrated 
datasets and provide the reference point for particle 
characterisation in terms of morphology and stability.
Regulatory and governance framework
The working group raised no new ethical issues for 
nanotechnologies beyond those already established for 
other technologies. Indeed, nanomaterials can be viewed 
as possessing intrinsic societal value in the context of 
sparing resources and contributing to social, economic 
and environmental sustainability. It is acknowledged that 
public concerns have been voiced about nanotechnology 
and such concerns are prone to amplification in 
sensationalist media accounts. 
It is important for the European Commission and European 
national authorities to encourage social science research 
exploring public attitudes. We observe that public 
engagement is likely to be more effective if there is shared 
understanding about the boundaries of nanotechnology 
and the appropriate balance of benefits and risks.
Regulation is challenging today because of uncertainties 
in definition and behaviour of nanomaterials, because 
of their application in many different industrial sectors 
and the lack of appropriate standards and validated 
testing procedures. The legislative framework can be 
distinguished as sector-specific (e.g. for cosmetics, 
medicines, foods) or horizontal (e.g. for chemicals, worker, 
consumer, environmental protection). 
■
■
■
■
■
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a variety of initiatives, including legislation on chemicals 
(e.g. Registration, Evaluation, Authorisation and Restriction 
of Chemicals (REACH)) and on occupational health and 
safety protection. There will be additional product-specific 
(e.g. food and cosmetic products) regulatory challenges. 
Further, into the future, it is important to understand how 
nanoparticle-based systems combining disease imaging 
and therapeutic delivery should be regulated—as a drug 
or medical device?
Agreeing codes of conduct and other voluntary measures 
is vital in advance of regulatory reform. In 2008, the 
European Commission adopted a Code of Conduct for 
nanoscience and nanotechnology—it is important to 
monitor its implementation and revise as appropriate. 
Manufacturing initiatives are also welcome in developing 
risk management systems based on best practice with 
reporting schemes that collect information on the 
characteristics and use of nanomaterials. 
Our recommendations: measures needed to 
understand and manage benefits versus risks of 
engineered nanomaterials
To manage benefits versus risks of engineered 
nanomaterials, the EU needs a coherent strategy in 
nanotechnology that has the flexibility to respond to future 
developments. This strategy must be multidisciplinary 
and multi-sectoral, requiring new effort in data collection, 
new infrastructure and new training initiatives, involving 
academia, industry, policy-makers and others in society.
The current safety assessment approach for nanomaterials 
is to start from a precautionary perspective and refine 
the strategy once sufficient knowledge is available to 
understand hazards, exposure potential and the means 
to protect workers, consumers and the environment 
from unwanted levels of contact. This is analogous to 
the European Chemicals Legislation (REACH) process. 
The challenge is to accomplish this assessment when the 
number and extent of industrial applications is growing 
rapidly, and to ensure that benefit–risk is judged rather than 
risk alone. If nanotechnology is to realise its potential, it is 
vital to empower the research and regulatory community 
to apply the precautionary principle in a focused and 
cost-effective manner. Risk assessment and management 
requires intelligent and case-specific consideration 
guided by potential exposure scenarios. It is also relevant 
to note that new knowledge will help to engineer safer 
nanomaterials.
We emphasise some cardinal points for the European 
Community:
Safety research is an essential part of the innovation 
of nanomaterials and has to take place during the 
innovation process (‘safety by design’).
Research planning/management and product 
regulation must be sufficiently flexible to cope with 
future developments.
Over-regulation should be avoided as it can slow 
down an improvement of the total benefit–risk 
balance in case regulation prevents industries 
from adopting novel techniques that would lower 
traditional risks. It may therefore act as an obstacle 
to innovation and research, and may prevent the 
translation into products that, when used in a safe 
manner, can contribute to EU societal objectives.
 
The main conclusions and recommendations in our report 
cover priorities for the following: 
Research and its translation into applications – 
there is scope to do more to integrate safety 
assessment into projects dealing with the 
development of new materials. The pharmaceutical 
sector can be considered as a relevant model 
where hazards and risks are addressed at an early 
stage in research. The research communities across 
nanomedical, nanoengineering and nanosafety 
are not yet well-linked and cross-talk should 
be encouraged in addition to teaching basic 
understanding about related fields. 
Funding strategies of the EU and its Member States 
need orchestration, identifying the strategic research 
questions and methodological developments to 
be pursued. It is important to avoid duplication in 
setting up new safety research centres. The long-
term use of simple engineered nanomaterials like 
metal oxides over the past three to four decades 
suggests that the newly emerging nanomaterials of 
higher sophistication may also find use in diverse 
applications, resulting in sustained public exposure. 
Measurements and monitoring of these nanomaterials 
is currently extremely tedious or cannot be done at 
all. Risk assessment cannot be confined to studying 
short-term effects after acute exposure but must 
also examine the potential for chronic effects arising 
from cumulative exposure. It is vital both to support 
basic safety research to fill knowledge gaps and to 
translate that knowledge more effectively. There are 
new opportunities, provided for example by meta-
analysis and modelling, to maximise the value of the 
knowledge already available.
Connecting science and regulation – the European 
Commission together with the European scientific 
community should strengthen efforts to define and 
implement a common terminology and identify 
common needs for data collection for safety 
endpoints that enable comparison of results from 
disparate groups and nanomaterials. 
The European Commission and European Agencies 
should continue to review the regulatory landscape 
and develop the evidence base to respond to queries 
from the European Parliament on whether the law 
■
■
■
■
■
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8specific to nanomaterials is adequate.  Introduction of 
a definition of nanomaterial in the Cosmetic Product 
Regulation has created a precedent for adopting a 
definition in other product areas and renders urgent 
harmonisation of a definition. 
A definition or any other standardising intent must 
be science based, unambiguous and enforceable 
if it is to facilitate progress and be successfully 
implemented.
Public engagement – it is also important that the 
European Commission together with the scientific 
community should make provision of accessible 
and accurate information about nanomaterials, 
emphasising that their risks are assessed according 
to the same principles applied in the assessment 
of other products. This communication activity 
must deliver balanced description in lay language 
and must describe both the potential societal 
benefits of scientific advances and the societal 
protection afforded by proportionate, sector-specific 
regulation.
Nanospecific training – modules can be included 
in EU research programmes. There is also broader 
■
■
need for training toxicologists, material scientists 
and production engineers in the risk assessment 
procedures for developing new materials. Training 
should be incorporated into both Master’s and PhD-
level activities, building on current best practice, for 
example the Marie Curie PhD training programme in 
nanotechnology safety. 
The development of new generations of nanomaterials 
requires a new generation of interdisciplinary 
scientists. New training initiatives are essential to 
confer this interdisciplinarity and secure the future of 
nanotechnology.
In conclusion, we reiterate that there is only a limited 
amount of scientific evidence to suggest that nanomaterials 
present a risk for human health and we advise that the 
principles of risk assessment procedures should conform 
to the same procedures as any other new material, paying 
due respect to new phenomena that may occur due to 
new properties related to the nanoscale. 
Successful innovation, if it is to encompass both regulatory 
and consumer approval, must incorporate safety by design. 
EXECUTIVE SUMMARY
93 International Organization for Standardization, ISO/TR 8004-1.
4 Loevestam, G. et al., European Commission, Joint Research Centre, EUR 24403 EN (2010) and papers cited therein.
5 Auffan, M. et al., Nature Nanotechnology 4, 634 (2009); Brune, H. et al., Ethics of Science and Technology Assessment 27, 11 (2006).
6 Shvedova, A.A. et al., Annual Review of Pharmacology and Toxicology 50, 65 (2010); Rothen-Rutishauser, B.M. et al., Environmental Science & 
 Technology 40, 4353 (2006); Wick, P. et al., Environmental Health Perspectives 118, 432 (2010).
1 Introduction
1.1 Development and use of nanotechnology
Nanotechnology is an enabling technology that has 
the potential to bring benefits to multiple areas of 
research and application and to enrich our lives in 
many ways. It is attracting rapidly increasing investment 
from governments and businesses around the world. 
Currently, relevant industrial sectors include those 
associated with, for example, information technologies, 
electronics, energy generation and storage, material 
sciences, bio-physico-chemical processing and catalysis, 
food and feed refinement, environmental remediation, 
security, transport and space, diagnostic and therapeutic 
applications in medicine. 
It is becoming clear from the scientific perspective 
that advances in the handling of atoms and molecules 
will increasingly allow manipulations in a targeted 
way, making use of structure-dependent molecule-to-
molecule interaction and processing. These ‘bottom-up’ 
scientific and technological principles and practices will 
be complemented by ‘top-down’ industrial strategies 
enabling the general introduction of engineered 
nanomaterials or nanoparticles of smaller and smaller 
sizes in many different applications. 
As the particle size shrinks, the proportion of molecules 
and/or atoms on the surface increases, leaving lesser 
proportions located within the inner volume of 
nanomaterials and enhancing and altering surface 
reactivity, modulated by the surface curvature and 
structure. Nanotechnological tools are increasingly 
available to allow such manipulations under greater 
control. Realistic opportunities for application are 
appearing on the horizon but, at the same time, there is 
need to guard against hyperbole expressed about both 
benefits and risks. 
It is important to achieve a common understanding of 
what is a nanomaterial. The boundary between nano- and 
other materials is not yet entirely clear and it is evident 
that nanomaterials cover a very broad range of entities 
and industrial applications. An overview on definitions of 
nanotechnology and nanomaterials is provided in Box 1.1 
and developments in this area have been informed by other 
important broader EU initiatives, for example the SCENIHR 
Scientific Committee on Emerging and Newly Identified 
Health Risks (whose activities are described in section 2.2.2). 
There is a potential evolution of nanotechnologies – 
ranging from a first generation of rather simple passive 
nanostructures through to a fourth generation of highly 
functionalised molecular systems (see Figure 1); more 
details on prospective benefits for certain applications 
are discussed in Chapter 3. Our report focuses on the 
impact of engineered nanomaterials on human health. 
In this respect, the term ‘engineered’ corresponds also 
to ‘synthetic’, ‘man-made’ or ‘manufactured’. But it should 
be noted that nanomaterials are also naturally present 
in the environment as nanoparticles in consequence, for 
example, of combustion processes. 
Box 1.1
Terms and definitions relating to nanotechnology 
and nanomaterials
Nanotechnology is a broad term, referring to the delibe-
rate creation, manipulation and application of structu-
res with one or more dimensions in the ‘nanoscale’. The 
nanoscale is often taken to refer to the size range from 
1 nanometre (nm) to 100 nm3, although these limits are 
not accepted by all involved in the field, and indeed the-
re are several particulate ‘nanomaterials’ that fall outside 
this range that are usually taken as being products of na-
notechnology.
A JRC Reference Report of 2010 on the subject of defi-
ning the term ‘nanomaterial’ stated that the term usually 
refers to ‘materials with external dimensions, or an inter-
nal structure, measured in nanometres that exhibit ad-
ditional or different properties and behaviour compared 
with coarser materials with the same chemical compo-
sition’.4 The European Commission will soon make a re-
commendation for a more precise regulatory definition, 
including specific limits for the relevant size range (see 
Chapter 2). The JRC report includes a non-exhaustive 
summary of definitions related to this issue and to nano-
technology in general. 
Several publications suggest that ‘nanomaterials’ should 
not be exclusively defined in terms of a size range (e.g. 
between 1 and 100 nm), but that specific new effects that 
the material exhibits below a size threshold should also 
be taken into account5. For many effects (e.g. quantum 
effects) this threshold is considerably less than 100 nm. 
In this regard it is important to note that some particles 
below a certain size threshold interact with living cells in 
a different way than their larger counterparts (see Chap-
ter 3). This biological threshold has been shown6 to be 
larger than 100 nm.  
An understanding of the size distribution within a nano-
material is also essential.
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1.2 Safety considerations
New technologies have potential to bring benefits as 
well as disadvantages in the exposure of humans to new 
materials. There are three main contexts for considering 
safety: environmental pollution, unintentional human 
exposure (e.g. because of pollution or exposure in 
the workplace) and purposeful human exposure (the 
intended applications). The exposure of populations in 
the workplace and consumers and of the environment to 
nanomaterials is likely to rise significantly. 
The complexity of the consequences for the benefit–risk 
balance is illustrated in the application of nanomaterials 
in the clinical field, where the very same properties that 
are desirable, such as the ability to cross biological barriers 
and the high degree of surface reactivity, may also give 
rise to unexpected and adverse effects.  
Although there is already considerable knowledge 
on the impact of those environmental nanoparticles 
produced unintentionally (e.g. through combustion 
processes), on human health primarily mediated 
through respiratory pathways, there are still deficits 
in the appropriate risk assessment methodology to 
evaluate the safety of engineered nanomaterials. In 
common with every other new technology, research 
and development (R&D) of nanomaterial products needs 
to be accompanied by safety assessment, including risk 
assessment and risk-management. Risk assessment 
and management requires intelligent and case-specific 
consideration guided by potential exposure scenarios. 
Figure 1: Evolution of nanotechnologies
In very many applications, nanomaterials are embedded 
in large structures (e.g. electronics, information techno-
logy; see Box 1.2). 
Box 1.2
Free versus embedded nanomaterials
There are different physical states, in particular free and 
embedded, that have a major effect on exposure. Howe-
ver, embedded forms may become free, for example by 
manipulations or erosion. Therefore, it is critically impor-
tant to take into perspective lifecycle analysis. One promi-
nent example may be carbon nanotubes, which are mainly 
embedded in composites and, therefore, exposure during 
manufacturing and potentially during subsequent mani-
pulation such as recycling may be the principal concern7.
7 Poland, C.A. et al., Nature Nanotechnology 3, 423 (2008).
In these cases they are likely to pose low risk because 
of minimal consumer exposure and environmental 
release, at least during their lifetime, before disposal and/
or recycling. However, it is important to take a whole 
lifecycle approach (from manufacturing to use to waste 
management) in considering impact. 
By comparison, other engineered nanoparticulate 
materials, for example in food and nutritional ingredients, 
paints and coatings, cosmetics and healthcare products, 
nanomedicinal drug applications, and textiles, might lead 
to substantial direct exposure and may, therefore, pose a 
potential risk to humans and the environment. 
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These cases require careful risk assessment and 
management based on realistic exposure scenarios of 
well-identified groups within the European population. 
Furthermore, experience accruing from the long-term use 
of simple nanomaterials such as metal oxides or carbon 
black over the past three to four decades suggests that 
(if the analogy applies) the newly emerging materials of 
higher sophistication may also find their way into many 
diverse applications, leading to long-lasting exposures of 
the public. 
The wide variety of consumer products within categories 
such as health and fitness, home and garden, electronics 
and computers makes it difficult to devise and verify a 
generic exposure assessment and risk management for 
nanoproducts as a class; the principles of sector-specific 
regulatory practice introduced for other products should 
also be applied to nanomaterials. Chapter 3 gives an 
extensive overview on the current knowledge concerning 
the impact of nanotechnology on human health and 
will demonstrate how proportionate risk assessment 
methodologies can be applied.
1.3 Response by public and private organisations: 
the current situation 
As noted above, a potential impact of nanomaterials on 
human health is often anticipated but in reality often not 
quantified. This relative lack of evidence has led both to 
articulation of public concern and commitment by public 
policy-makers to strengthen the regulatory environment. 
However, it can also be said that the scientific community 
is relatively well prepared by comparison with the 
situation that has often characterised the advance of other 
enabling technologies. In the rapidly growing field of 
nanotechnology, questions about potential risk have been 
posed early on—and probably much earlier than in other 
technological advances. There are strong expectations 
that this attention to possible risks will be an additional 
and innovative driver to guide nanotechnologies into 
a safe and sustainable future for human health and 
environmental protection. 
Research projects that include safety assessment are 
performed worldwide. Therefore, it is of vital importance 
to ensure that comparable results are obtained in 
order to create coherent science- and evidence-based 
risk assessment and management. This comparability 
objective requires harmonisation and standardisation 
of test methods, test materials and data, as discussed 
in Chapters 2, 3 and 4. Despite the growing use of 
nanomaterials in consumer products and innovative 
technological applications, there is at present no widely 
accepted definition of the term ‘nanomaterial’ that is 
suitable as a basis for legislation on their safe use (see 
Box 1.1 for background). Any definition in legal terms 
will have implications according to the context in which 
it is used and may need adaptation for specific European 
regulations or directives. It is, however, of the utmost 
importance to have a definition available for it has a 
significant impact on research for safety assessment (see 
Chapter 2 for further discussion). 
It is important to appreciate – especially in terms of 
exposure assessment – how many products containing 
nanomaterials are already available to consumers. Since 
2006, there has been a voluntary database (Woodrow 
Wilson inventory8) accessible to consumers. In 2006, 
the inventory contained about 200 different products, 
increasing to nearly 600 products in 2007, with product 
number 1,000 added in 2009. The Woodrow Wilson 
inventory is indeed a valuable source of information about 
commercially available nano-products, but it should 
be noted that inclusion in the database is made on the 
producer’s claim that the product is a ‘nano-product’. Thus, 
the actual nanomaterials used in the consumer products 
are not always known9. To overcome these uncertainties, a 
mandatory European Register of those nanoproducts on 
the market has been requested by a growing number of 
EU Member States and by the European Parliament. The 
European Commission is currently assessing the needs 
and requirement for such a database. 
1.4 Aim of the present report
As mentioned previously, several studies have examined 
the effect of environmental nanoparticles, for example 
generated from combustion processes, on human health. 
However, there is no generally applicable paradigm 
for safety assessment of consumer and other products 
containing nanomaterials. 
This deficit is widely acknowledged, not only by the 
research organisations studying effects and interactions 
of nanomaterials at the cellular level and developing 
risk assessment methodologies, but also by policy-
makers and their advisory bodies. A report released by 
the European Parliament10 and another by the German 
NanoCommission11 are recent examples where decision-
makers are calling for more advice. 
The objective of the present report is not just to review 
the current state-of-the-art concerning research on 
nanotechnology safety but, in addition, to identify the 
gaps for further research, its translation and the related 
actions necessary to achieve the goal of a science-based 
evaluation of the impact of nanomaterials on human 
health. There is already a large literature and we have 
  8  Woodrow Wilson Center: www.nanotechproject.org/inventories/consumer. 
  9  Hansen, S.F. et al., Ecotoxicology 17, 438 (2008).
10 European Parliament, Science and Technology Options Assessment (STOA), PE 446.050 (2010).
11 German Federal Government, NanoKommission: Verantwortlicher Umgang mit Nanotechnologien (2011).
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cited key publications to exemplify issues to guide further 
discussion. It is not the purpose of this report to provide 
formal guidelines (e.g. on definition), for which more 
discussions are needed within the scientific community, as 
it is important to recognise that research on nanomaterials 
is rapidly advancing.
Different levels of controls may be needed for different 
categories of nanomaterials and the likelihood that they 
can be dispersed during use and coming into contact with 
human beings (see Box 2.1). Therefore, the main focus of 
this report is on free nanomaterials. 
Both organisations involved in this report, the JRC and 
EASAC provide independent science-based evidence 
and advice to European policy-makers and citizens. 
Whereas the JRC has in-house expertise and laboratories 
in nanotechnology research, EASAC has access to first-
class research through its Academy members and their 
academic networks. A strategic liaison between our two 
organisations was agreed to generate a first joint policy 
report in order to achieve the strongest possible impact 
for our advice on this very important topic for Europe. 
A working group was established in 2009 to consider issues 
for the possible impact of nanomaterials on human health, 
focusing specifically on engineered nanomaterials. 
The working group was given the remit to (1) describe the 
state-of-the-art in regard to benefits and potential risks; 
(2) review current methods for safety assessment and 
evaluate their relevance; (3) identify knowledge gaps in 
studying the safety of nanomaterials; and (4) recommend 
priorities for nanomaterial research and the regulatory 
framework. 
This report focuses on key principles and issues, cross-
referencing other sources for detailed information, rather 
than attempting a comprehensive account of the science. 
The focus is on human health although environmental 
effects are also discussed when directly relevant to 
human health. Our aim is that this joint initiative between 
EASAC and the JRC will lead to wide dissemination of our 
recommendations to audiences in academia, industry, 
the policy-making community and other stakeholders, to 
support the collective goal of safe nanotechnology-based 
products on the European market. 
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2 Legal and Societal Implications of Nanosafety:  
 Regulations and Governance
2.1 Societal issues and risks perceptions
Advances in nanotechnology raise questions about 
how to deal with uncertainty when there is insufficient 
knowledge regarding health impacts. Questions emerge 
at different ‘levels’ and range from the following:
very specific scientific queries on how to understand 
the interaction of nanomaterials with the human 
body, to 
concerns of consumers on the safety of products and 
the general benefits for the use of nanotechnology, 
and finally to 
policy questions on how to address safety issues 
and concerns from the regulatory side and how to 
develop appropriate governance systems to cope 
with the novelties of nanotechnology. 
These questions have, therefore, also to be addressed on 
different levels by using appropriate approaches. These 
include use of research funding to provide new information, 
regulatory actions, self-regulation, governance structures 
to assure transparency and comprehensive information, 
stakeholder involvement, as well as public engagement 
and dialogue, as discussed subsequently in this and the 
following chapters. It should be emphasised that the 
issues for nanotechnology are not different in principle 
to any other emerging technology, where appropriate 
tools and practices for dealing with potential risks must 
be developed. However, ethical issues and societal 
concerns are not always clear-cut and may become more 
pressing with the increasing uses or potential misuses 
of nanotechnologies. Public engagement to address 
concerns may require different policy instruments from 
those technical tools applied to deal with the regulation 
of safety risks. 
As described in Chapter 3, nanotechnology holds 
considerable promise in many different technological 
areas. To realise progress, it is necessary to adopt an 
‘integrated, safe and responsible’ strategy as already laid 
down in the first Action Plan of the EC12. 
Innovation through the development of nanotechnology-
based products must ensure a high level of human health, 
worker safety and environmental protection in order to 
obtain and secure consumer confidence and workers’ 
trust. For this reason an integrated approach must foster 
both innovation and safety by addressing all safety issues 
while enabling industry to enhance its competitiveness. 
Activities on the governance of nanotechnologies 
should encompass all issues related to environment, 
health and safety (EHS) and take due account of ethical, 
legal and social aspects (ELSA). This requires the use 
of appropriate instruments13 including the following: 
Knowledge gathering.
Self-regulation and voluntary measures.
Regulation by adaptation of the existing regulatory 
framework.
Transnational collaboration.
These instruments are applied according to the different 
timescales for which actions are desirable and progress 
can be achieved: for example, information gathering and 
funding of research programmes as immediate action; 
adoption of voluntary measures and self-regulation by 
involvement of relevant stakeholders in the short to 
medium term; the implementation of regulation, taking 
into account specific nanotechnology issues, in the 
medium/longer term. These activities are discussed in 
further detail in the following sections.
At the present time, concerns about nanotechnology 
products and their perceived risks relate mainly to 
materials that are in a particulate form at the nanoscale, 
and which are mobile in their immediate environments. 
For this reason, current activities about regulation and 
governance of nanotechnology concentrate on ‘free’ 
engineered nanoparticles and their applications as part 
of the focus on first-generation, passive nanomaterials 
(see Figure 1 in Chapter 1), but as described previously 
(Box 1.2) it is also important to take account of possible 
changes during the product lifecycle, for example when a 
composite product is manipulated. 
An urgent need for appropriate legislation to manage 
the potential risks of nanomaterials was communicated 
in a non-binding resolution adopted in April 2009 by the 
European Parliament14. In this resolution, it was questioned 
whether current EU legislation is adequate to deal with 
the potential health, environment and safety hazards of 
nanomaterials and the Commission was requested to 
review all relevant legislation by 2011. 
The Parliament considered it particularly important to 
address nanomaterials explicitly, at least within the scope 
of legislation on chemicals, food, waste, air and water, and 
worker protection. The Parliament’s opinion also included 
several specific requests to the Commission, about certain 
■
■
■
■
■
■
■
12 European Commission: http://ftp.cordis.europa.eu/pub/nanotechnology/docs/action_plan_brochure.pdf.
13 Observatory Nano Project: http://www.observatory-nano.eu.
14 European Parliament, A6-0255/2009 (2009).
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aspects of regulation, the definition of nanomaterials, 
labelling, ethics, the involvement of stakeholders, fact-
finding, research and co-ordination.
Recently, two reports were published considering scientific 
knowledge, risk aspects and scientific governance, which 
are relevant to our present report: the Nanosafety report 
(interim report phase II) on manufactured nanoparticles 
by the European Parliament14 (the STOA Report; see 
Box 2.1) and the EASAC Policy Report Number 13 on 
Synthetic Biology15 (see Box 2.2). The STOA Report will 
be of particular importance in informing and stimulating 
further discussion with politicians at the European level 
but, of course, there is also need to build engagement with 
politicians at the national level and with policy-makers in 
the other European institutions. 
The previous EASAC Report covers various specific issues 
for safety, security, public involvement and product 
regulation for synthetic biology that are also very relevant 
for nanomaterials. Taken together, it is hoped that these 
two reports with our present report and other relevant 
outputs (for example, from the recent Nanomedicine 
Roundtable and other initiatives in public engagement 
(see Chapter 4), will provide a very useful collective 
resource for communicating strong evidence-based 
messages. Relevant issues outlined in the two boxes (2.1 
and 2.2) will also be discussed in further detail in the 
following chapters. 
Of course, the issues are not confined to Europe. 
Transnational collaboration is an important aspect of 
nanotechnology governance, because all countries face in 
principle the same ethical, legal and societal implications 
and related problems, the degree depending on their 
involvement through industrial activities, public research 
funding and regulatory assessment. In the EU, Member 
States follow closely the developments on Community 
level, several countries with strong involvement in 
nanotechnology development, for example Germany, 
UK, France and the Netherlands, have launched activities 
at a national level (see section 2.2.1). Furthermore, 
international collaboration with the USA, Canada and 
Australia and Asian countries, in particular, Japan, China, 
India and Taiwan, is being intensified at various levels 
regarding governance, research and regulatory activities, 
as well as attending to standardisation and harmonisation 
issues.
15 EASAC Policy Report 13, EASAC, Halle (2010).
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Box 2.1
Summary of findings from the European Parliament, 
Science and Technology Options Assessment (STOA) 
report on nano-safety – risk governance of manufac-
tured nanoparticles
The STOA report gives a brief review of regulatory acti-
vities about manufactured particulate nanomaterials at 
the European level, discusses advantages and limitations 
of selected regulatory instruments and presents first ide-
as for options for parliamentary action.
The report concludes that risk assessment needs further 
information on hazard and exposure. Nanoscale parti-
culate material implies novel material properties which 
may lead to novel health and environmental risks. Cer-
tain nanomaterials may induce pathologic conditions 
at high dose (hazard) and/or over a long period of time 
(exposure). 
Data available provide a basis for further investigations 
on fate and behaviour in the environment and on toxici-
ty, including clarification of underlying mechanisms. But 
there are only limited data available on the hazard and 
fewer on exposure. Therefore, information is needed on 
acute and chronic exposure, appropriate instruments to 
assess exposure and hazards, toxicity studies of particu-
late material on a case by case basis, investigation of the 
biological relevance and dose dependence.
The STOA report suggests various actions, to foster re-
search activities and their co-ordination internationally, 
standardisation of methods, publication of no-effect 
data, the independent systematic review of information 
and the multidisciplinary training of young scientists.
Summary of findings of the EASAC Policy Report 13: 
“Realising European potential in synthetic biology: 
scientific opportunities and good governance”
Synthetic biology is the engineering of biology; it is de-
liberately designing and constructing novel biological 
systems to perform new functions. The report is deri-
ved from activities by national academies of science to-
gether with analysis and advice from an EASAC expert 
Working Group. It recommends identifying features that 
distinguish synthetic biology from systems biology and 
other technologies, exploring what contribution synthe-
tic biology might make to tackle EU societal needs and 
economic growth, assessing what is needed to create an 
appropriate regulatory environment and clarifying the 
implications for EU policy-making priorities.
Synthetic biology will lead to a better understanding of 
natural biological systems. Scientific advances in metho-
dology, where EASAC identifies continuing opportuni-
ties for European research include, minimal genomes, 
i.e. the smallest number of parts needed for life (basis for 
engineering minimal cell factories for new functions), or-
thogonal biosynthesis (engineering the cells to expand 
the genetic code), regulatory circuits (artificial networks 
to provide new functions in cells and organisms), meta-
bolic engineering (new levels of complexity), protocells 
(synthetic cells) and bio-nanoscience (molecular-scale 
motors for cell-based machines or cell-free devices to 
perform complex new tasks). Some research directions 
in synthetic biology overlap with nanotechnology: issues 
for biosafety may also be relevant for nanotechnology.
Synthetic biology offers the potential to engineer new 
levels of safety into the applications. It is concluded, 
that existing legislation is adequate as long as synthetic 
biology remains an extension of recombinant DNA tech-
nology and the scientific community commits to develo-
ping voluntary codes of conduct.
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2.2 Regulation and governance
2.2.1 Regulatory landscape
As will be indicated in Chapters 3 and 4, there are still 
significant gaps in the understanding of nanomaterials and 
their impact on health and the environment. Moreover, 
the absence of an accepted definition of nanomaterials 
(Chapter 1), their application in many different industrial 
sectors, and the lack of appropriate standards and testing 
procedures, imposes obstacles to progress on regulation 
that must now be overcome. So far, nanomaterials and 
related products are dealt with under existing broader 
regulatory schemes and worldwide there are only very 
few examples where nanospecific regulation has been 
put in place. Recently, an overview of the worldwide 
regulation landscape has been compiled within the 
Framework Programme 7 project ObservatoryNano and 
some findings are outlined below. 
In general, regulatory authorities in Europe, the USA, 
Canada and Australia have become more proactive in 
recent years to cope with the complex issues for the 
regulation of nanomaterials and products. The European 
Commission, Canada and Australia, in particular, have 
adopted an approach that provides guidance and adapts 
regulation for nanotechnologies. Asian countries such as 
China, Japan, India and Taiwan are looking to Europe (and 
the USA) for information in developing their legislation 
dealing with nanomaterials and products thereof. 
With respect to relevant EU legislation, a distinction can 
be made between horizontal legislation (e.g. chemicals 
legislation, worker protection and environmental 
legislation) and sector-specific legislation (e.g. cosmetic 
products, food legislation, biocidal products, medicinal 
products, medical devices, electrical and electronic 
equipment). In general, current EU legislation applies 
to nanomaterials without specifically addressing them. 
However, the Commission acknowledges that regulatory 
changes may be needed, based on new scientific findings. 
Discussions about legislative initiatives on nanomaterials 
are also taking place at national level in some EU Member 
States, in particular in France, Germany, the Netherlands, 
UK, Austria, as well as in other countries, in particular 
Switzerland and Norway. 
Though on regulatory matters the European Member 
States tend to follow the inputs from the EC, several 
countries have activities at the national level of their own. 
Most of the other European countries have also started 
activities on nanotechnology regulation mainly with 
respect to REACH and occupational and health safety 
aspects of nanomaterials. 
2.2.2 Nanospecific adaptations of EU regulations
As noted in the previous section, initiatives for the 
adaptation of regulation to take into account the specific 
attributes of nanomaterials are proceeding worldwide 
with different emphasis according to the national 
involvement in nanotechnology developments and 
traditions in legislation and regulation. 
In Europe, issues about regulation of nanomaterials were 
discussed in different Scientific Opinions of working 
groups and technical committees of the European 
Commission and EU Agencies16. Based on an internal 
regulatory review, the European Commission adopted the 
Communication ‘Regulatory Aspects of Nanomaterials’ in 
June 2008, concluding that the existing EU regulatory 
framework ‘covers in principle the potential health, safety 
and environmental risks in relation to nanomaterials’17. 
It is, however, acknowledged that regulatory changes 
may be needed in the light of new information becoming 
available. In its resolution, adopted in April 2009, the 
European Parliament16 queries this position and, in 
addition to the request for a regulatory review by 2011, 
it states that the current EU legislation is inadequate and 
that nanomaterials should be explicitly addressed. 
At present, the regulations governing the areas of 
chemicals and materials, medical devices, cosmetics, 
pharmaceuticals, foods, as well as horizontal regulation 
related to occupational health and worker safety, and 
environmental safety are scrutinised for nanospecific 
provisions. Moreover, following the requests of the 
European Parliament, horizontal aspects are being 
discussed by the European Commission to cover the 
definition of nanomaterial, labelling of nanomaterials 
in products, and the establishment of a nanomaterial 
inventory at Commission level. 
2.2.2.1 Chemicals: REACH
The most comprehensive horizontal piece of legislation 
relevant to nanomaterials is the EU chemicals legislation, 
REACH (Registration, Evaluation, Authorisation and 
Restriction of Chemicals)18. REACH applies to chemical 
‘substances’ on their own, in mixtures or in products. 
Although there are no provisions in REACH referring 
specifically to nanomaterials, the scope of REACH includes 
chemical substances, in whatever size, shape or physical 
state (CA/59/2008 rev.1)19. 
Substances at the nanoscale are therefore covered by 
REACH and its provisions apply. The same consideration 
applies to other legal instruments that use the same 
16 SCENIHR Opinion, 10.03.2006; SCENIHR Opinion, 29.11.2007; Scientific Committee on Consumer Products (SCCP) Opinion, 18.12.2007; European  
 Food Safety Authority (EFSA) Opinion, 10.02.2009.
17 European Commission, COM(2008) 366 final 17 June 2008.
18 European Commission, Regulation (EC) No 1907/2006 – OJ L 136, 29.5.2007, p. 3.
19 Nanomaterials in REACH (CA/59/2008 rev.1).  
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(Biocidal Products Directive20 and Cosmetic Products 
Regulation21) or a similar (Plant Protection Products 
Directive22) substance definition as REACH.
Concerns that have been expressed about REACH relate 
to its applicability for the chemical safety assessment of 
nanomaterials because of the lack of knowledge about 
their physico-chemical features and effects on human 
health and the environment. Moreover, REACH registration 
and chemical safety assessment requirements depend 
on the volume of the chemical substance manufactured 
or imported on an annual basis (currently 1 tonne/year 
threshold level for registration and 10 tonnes/year for 
conducting a chemical safety assessment, although 
discussion is continuing as to whether these are the 
appropriate thresholds). These limits may put some 
nanomaterials manufactured or imported in lower volumes 
outside the requirements of registration. However, it 
should be noted that other provisions in REACH, such as 
requirements for classification and labelling, provisions 
of Safety Data Sheets, as well as the Authorisation and 
Restriction procedures apply without a threshold level.
To exchange views on existing and future implementation 
issues and other matters related to nanomaterials under 
REACH, the REACH Competent Authorities Sub Group on 
Nanomaterials (CASG Nano) was created in March 2008. 
The group will provide recommendations to the REACH 
Competent Authorities and advise the Commission 
taking into account stakeholder views. In support of 
the Group, the JRC Institute for Health and Consumer 
Protection has performed and co-ordinated three REACH 
Implementation Projects on Nanomaterials dealing 
with (1) the substance identification of nanomaterials, 
(2) information requirements on intrinsic properties of 
nanomaterials and (3) exposure assessments and hazard 
and risk characterisation of nanomaterials.
2.2.2.2 Medical devices and medicinal products
Medical devices and medicinal products are subject 
to a detailed authorisation procedure and the existing 
provisions are generally considered adequate for 
products containing nanomaterials. The evaluation and 
authorisation procedures of such products should properly 
take into account specific properties of nanomaterials 
in the various applications. A particular problem for 
the application of nanomaterials in this field arises 
with possible complex mechanisms of action causing 
a blurring of borderlines between different regulatory 
and classification systems (e.g. those appertaining to 
therapeutic, diagnostic and imaging products). For 
both medical devices and medicinal products there are 
activities continuing at the European level, discussing 
the consequences of advances in nanomedicine for risk 
assessment and the development of guidance. 
2.2.2.3 Cosmetics
The European Parliament and the Council have adopted 
the new Cosmetic Products Regulation, which will enter 
into force in July 2013 and which introduces various 
provisions specific to nanomaterials. These provisions 
include a notification obligation for manufacturers about 
the presence of nanomaterials in cosmetics not subject 
to prior authorisation; a possibility for the Commission 
to request a safety assessment for such materials by the 
Scientific Committee for Consumer Safety; and a labelling 
requirement for nanomaterial ingredients. This means 
that in the list of ingredients the names of such substances 
shall be followed by the word ‘nano’ in brackets. 
The Cosmetic Products Regulation also introduces a 
definition of nanomaterials: ‘‘nanomaterial’ means an 
insoluble or biopersistent and intentionally manufactured 
material with one or more external dimensions, or an internal 
structure, on the scale from 1 to 100 nm’. The Regulation also 
includes a review clause, which states that the definition 
shall be adapted to technical and scientific progress. Other 
Regulations/Directives with such provisions might follow.
2.2.2.4 Definition of nanomaterial
The introduction of provisions specific to nanomaterials 
requires the adoption of a definition. Consequently, the 
regulation on cosmetics and the future regulation on the 
provision of ‘Food Information to Consumers’ introduced 
a definition (more details below). However, in view of 
the various definitions of nanomaterials published by 
different bodies, and the constant technical and scientific 
developments in the field (Box 1.1, Chapter 1 and see 
later in this chapter), the Commission is given a mandate 
to adjust these definitions in the light of technical and 
scientific progress, and to align them with definitions 
subsequently agreed at international level. This raises 
the question as to whether an overarching, ‘harmonised’ 
definition of nanomaterial across the different regulatory 
areas would be appropriate23. 
An advantage of different definitions would be that 
the definition could be tailored to the needs of specific 
legislative instruments. However, a chemical substance 
might be used in different industrial sectors and areas of 
application. Thus, different definitions would lead to the 
situation, that the same substance could be regarded as a 
nanomaterial under one legal instrument, but not under 
another. To avoid such confusion, a common definition 
20 European Commission, Directive 98/8/EC concerning– OJ L 123, 24.4.1998, p. 41.
21 European Commission, Regulation (EC) No 1223/2009– OJ L 342, 22.12.2009, p. 59.
22 European Commission, Directive 91/414/EEC - OJ L 230, 19.8.1991.
23 Maynard, A.D., Nature 475, 31 (2011).
LEGAL AND SOCIETAL IMPLICATIONS OF NANOSAFETY: REGULATIONS AND GOVERNANCE
17
would be desirable if it could be made broadly applicable 
in EU legislation and policies, for example in chemicals 
legislation, worker protection legislation, and legislation 
on air and water quality or waste. The implicit condition 
– even if difficult to achieve – is that such a common 
definition is suited for all the regulations and policies it 
intends to serve.
For legal instruments it is required that the definition is 
clear and unambiguous so that it is easy to implement. In 
addition, compliance checks must be possible, for example 
in order to assess whether the envisaged future labelling 
requirements for certain products could be fulfilled. 
Thus, the definition must be enforceable and this implies 
that appropriate measurement techniques are available 
and methods and procedures for their application are 
agreed. In recent reports considerations on elements for a 
definition for regulatory purposes6 and proposals for such 
a definition24 have been published.
The Commission had drafted a recommendation for a 
generally applicable definition which was subject to 
public consultation in 2010. A final decision on a 
recommendation taking into account opinions of 
stakeholders is still pending. To preserve the integrity 
of the EU internal market, it is necessary to ensure that 
such a definition is accepted by all EU Member States, 
thus avoiding claims of additional national regulatory 
needs. Furthermore, in light of the global market, a 
European definition should be in line with international 
initiatives, e.g. Organisation for Economic Co-operation 
and Development (OECD) and the standardisation 
bodies, the International Organization for Standardization 
(ISO). It should also be emphasised that each definition 
has implications within the context in which it is used. 
Therefore, any definition will also involve policy choices, 
and accordingly will inevitably entail political decisions. 
2.2.2.5 Labelling
The resolution of the European Parliament calls ‘for 
the provision of information to consumers on the use of 
nanomaterials in consumer products’ requesting that 
‘all ingredients present in the form of nanomaterials in 
substances, mixtures or articles should be clearly indicated 
in the labelling of the product’. 
As previously discussed, this stipulation has already 
been included in the European Regulation on Cosmetic 
Products22 where it is stated that all ingredients present in 
the form of nanomaterials shall be clearly indicated in the 
list of ingredients. The EP request has also been taken into 
account in a recent resolution of the European Parliament 
on the provision of ‘Food Information to Consumers’25. 
Amendments proposed for the Restriction of Hazardous 
Substances Directive, which places restrictions on the use 
of certain hazardous substances in electrical and electronic 
equipment, also include the request for notification of the 
use of nanomaterials, a standard for the identification and 
detection of nanomaterials, and harmonised labelling.
2.2.3 Self-regulation and voluntary measures
In the current phase characterised by the simultaneous 
rapid accumulation of scientific knowledge on nanosafety 
together with progressive penetration of the market by 
innovative nanotechnology products, where regulation 
faces difficulty to keep pace with the new developments, 
a culture of responsibility is necessary to maintain trust. 
As part of this responsibility, adopting voluntary measures 
for risk management systems and codes of conduct 
can have an important role in dealing with current 
uncertainties about the impact of nanotechnologies.
In February 2008 the Commission adopted a 
recommendation for a ‘Code of Conduct for responsible 
nanosciences and nanotechnologies research’26. It contains 
a series of principles and guidelines that Member States 
and ultimately all stakeholders in the field of research 
are invited to adopt and promote. The objectives are far-
reaching and among the principles that must be respected, 
(1) sustainability, (2) precaution, (3) inclusiveness, and 
(4) accountability, are of particular relevance. The Code 
of Conduct is voluntary and complementary to existing 
regulations. The Code will be monitored and revised every 
two years by the Commission to take into account new 
developments in nanotechnology.
In addition, because of the current uncertainty in the 
regulatory situation, some stakeholders, mainly at 
industrial level, have developed (or are developing) their 
own risk management systems, defining best practices 
and procedures for safety control and handling of 
nanomaterials in occupational settings. 
The DuPont/Environmental Defence Nano Risk 
Framework27 and the CENARIOS risk management and 
monitoring system28, are two examples of such an 
approach. Other voluntary measures involve the 
development of reporting schemes29. These instruments 
are used by regulatory authorities, for example Voluntary 
Reporting Scheme, DEFRA (UK)30 and the Nanoscale 
24 SCENIHR Final Opinion 08.12.2010.
25 European Parliament in Document P7_TA(2011)0324 
 http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-2011-0324&language=EN&ring=A7-2011-0177.
26 European Commission, Commission Recommendation of 07/02/2008.
27 Environmental Defense - DuPont Partnership June 2007, Nano Risk Framework, http://www.nanoriskframework.com.
28 CENARIOS - Certifiable risk management and monitoring system, TÜV SÜD Industrie Service GmbH and The Innovation Society.
29 Linkov, I. et al., Nanotechnology Law & Business 6, 203 (2009).
30 DEFRA, UK Voluntary Reporting Scheme for engineered nanoscale materials (2006).
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31 US EPA, Concept Paper for the Nanoscale Materials Stewardship Program under TSCA (2007).
32 Fiedeler, U. et al., Institute of Technology Assessment of the Austrian Academy of Sciences, Nanotrust-Dossiers No 16 (2010).
33 Swiss Federal Council, Action Plan Synthetic Nanomaterials (2008).
34 Swiss Federal Office of Public Health FOPH, Swiss Federal Office for the Environment FOEN, Guidelines on the precautionary matrix for synthetic  
 nanomaterials (2010). 
35 Swiss Federal Office for the Environment FOEN, Federal Office of Public Health FOPH, Grundlagenbericht zum Aktionsplan (2007).
36 See, e.g. http://ncl.cancer.gov.
Materials Stewardship Program, (US Environmental 
Protection Agency)31, to collect information from 
industry about the manufacturing, production and use of 
nanomaterials32. Information required includes material 
specifications, production volumes, risk assessment and 
risk management data, and methods to provide firmer 
evidence for regulatory and policy decisions. 
One other activity relevant in this context is exemplified 
by the Swiss Action Plan for Synthetic Nanomaterials33 
(see Box 2.3) which was the basis for the development 
of a precautionary matrix34 for products and applications 
that involve engineered nanomaterials. The matrix 
provides a structured method to assess the ‘nanospecific 
precautionary need’ of workers, consumers and the 
environment arising from the production and use of 
synthetic nanomaterials. The matrix is a tool to support 
trade and industry to meet their obligations of care and 
self-monitoring. It helps them to recognise applications 
that might entail risk and to take precautionary measures 
to protect human health and the environment. In the case 
of new developments, the matrix can contribute to the 
innovation of safer products. It enables users to conduct 
an initial analysis on the basis of currently available 
knowledge and indicates when further investigations are 
necessary.
Box 2.3
An example of a voluntary approach
The Swiss Action Plan on Synthetic Nanomaterials, based 
on a detailed report35 focuses on the following priority 
actions: 
Creating the scientific and methodological precondi-
tions to recognise and prevent the possible harmful 
impacts of synthetic nanoparticles on health and the 
environment.
Creating the regulatory framework for responsible 
handling of synthetic nanomaterials.
Promoting public dialogue about the opportunities 
and risks of nanotechnology.
Using better existing promotional instruments for the 
development and market launch of sustainable appli-
cations of nanotechnology.
This action plan aims to develop a precautionary matrix 
for products and applications that involve engineered 
nanomaterials as the core measure for empowering in-
dustry, commerce and trade to take greater responsibi-
lity in this area and to apply the precautionary principle 
in a targeted and cost-effective manner. This was the 
background for developing the Swiss precautionary ma-
trix for synthetic nanomaterials, which is intended as a 
screening tool for trade and industry to follow a struc-
tured approach to recognising the risk potential when 
dealing with engineered nanomaterials.
■
■
■
■
Box 2.4
Actions of OECD Working Party on manufactured 
nanomaterials
Development of a database on human health and 
environmental safety research.
Safety testing of a representative set of manufactured 
nanomaterials.
Manufactured nanomaterials and test guidelines.
Co-operation on voluntary schemes and regulatory 
programmes.
Co-operation on risk assessment.
The role of alternative methods in nanotoxicology.
Exposure measurement and exposure mitigation.
Environmentally sustainable use of manufactured 
nanomaterials.
■
■
■
■
■
■
■
■
The matrix described in Box 2.3 is already in use by a 
broad circle of applicants in Switzerland and elsewhere. 
It will be further developed in close co-operation with 
trade, industry and science as well as with consumer and 
environmental organisations. Despite this initiative and 
other voluntary actions and registries across Europe, there 
is also an ongoing debate on the need for mandatory 
registration. Some EU Member States are currently 
discussing the creation of an appropriate database, and 
this may result in the development of a European-wide 
registry with implications for labelling.
2.3 Standardisation and harmonisation of test 
methods 
Internationally harmonised standards and methods are 
indispensable for the evaluation of environmental, health 
and safety risks. The OECD and the standardisation bodies, 
the ISO and the European Committee for Standardisation 
(CEN) have established working groups and technical 
committees that play a key role in the development of 
measurement standards and formally recognised test 
methods and guidelines for nanomaterials. In the USA, 
there has been substantial work by the US National 
Nanotechnology Characterisation Laboratory, for example 
relating to nanomaterials for cancer therapies and 
diagnostics36. In Europe most test guidelines applicable 
under EU regulations are based on the work of the 
OECD. In 2006 the OECD established the Working Party 
on Manufactured Nanomaterials (WPMN), to promote 
international co-operation in the health, safety and 
environmental issues of manufactured nanomaterials. It 
is the main forum for international co-operation in this 
area for the development of test methods needed for the 
proper implementation of regulation. 
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The Working Party is implementing its work through 
specific projects to further develop appropriate methods 
and strategies as shown in Box 2.4. 
A flagship activity is the so-called ‘sponsorship 
programme’37 launched in November 2007. This pools 
resources from all of the OECD Member countries and 
industries in an effort to perform tests on an agreed 
priority list of 13 commercially relevant nanomaterials38. 
The outcome of this programme is expected in the next 
years and will serve as a very significant resource to support 
the implementation of enhanced safety requirements. 
A key condition is to make tests comparable, given the 
involvement of many independent research institutions. 
For nanomaterials this is a significant challenge because 
reference nanomaterials, measurement and dosimetry 
are still in continuing development. 
There is a close collaboration with the standardisation 
work of ISO and CEN. Standardisation activities for 
nanotechnology with relevance for European legislation 
are driven by ISO and CEN in the Technical Committees 
CEN/TC 352 and ISO/TC 229, both initiated in 2005. Several 
EU national bodies contribute to the ISO work; industry 
associations, consumer organisations as well as the EC 
have become liaison members. 
To avoid duplication, and because of the global relevance 
of harmonised standards, EU members have expressed 
their preference for the development of standards at the 
ISO level. For topics of mutual interest to both ISO and 
CEN, work is performed under the Vienna Agreement39, 
with an ISO or CEN lead. 
The contribution to the development of ISO standards 
by CEN is, incidentally, one way of involving in the 
nanotechnologies standardisation process those EU 
countries that do not have the means to participate at ISO 
level. 
Forty different ISO documents are currently being 
developed in ISO/TC 229 in the fields of terminology and 
nomenclature (JWG1); measurement and characterisation 
(JWG2); health, safety and environmental aspects of 
nanotechnologies (WG3); and materials specifications 
(WG4). Harmonisation of methods requires also other 
quality assurance tools such as standardised (reference) 
materials. 
The EC-JRC is supporting the activities of standardisation 
by maintaining a repository of currently 25 reference 
nanomaterials40 (including many of the OECD priority 
materials) which can be used for a harmonised safety 
assessment in research institutions.
37 OECD-WPMN Sponsorship Programme: http://www.oecd.org.
38 OECD: http://www.oecd.org/officialdocuments/displaydocumentpdf?cote=env/jm/mono(2010)46&doclanguage=en.
39 International Organization for Standardization: http://www.iso.org.
40 European Commission, JRC, IHCP: http://ihcp.jrc.ec.europa.eu.
LEGAL AND SOCIETAL IMPLICATIONS OF NANOSAFETY: REGULATIONS AND GOVERNANCE

21
3 Opportunities and Safety Considerations
A prerequisite of success for any new product on the 
market, whether or not containing nanomaterials, is to 
gain acceptance by consumers. As there is no such thing 
as zero risk, safety aspects need to be carefully examined 
to understand whether the expected benefits of new 
products outweigh the potential risks. Consumers accept 
risks more readily if there are clear benefits and if the risks 
can be controlled. As information on benefits is provided 
by many other published sources, our focus in this chapter, 
as in the report overall, is on the safety considerations. At 
the outset, we note that there is greater knowledge about 
the hazard assessment of engineered nanomaterials than 
there is about human exposure to such materials.  
3.1 Applications and characteristics
Nanotechnology has already demonstrated its great 
potential, as described in Chapter 1, and nanomaterials 
are increasingly used in innovative applications and 
products. Every-day consumer products may be made 
lighter, stronger, cleaner, less expensive, more effective 
and efficient, more precise, or more aesthetic. Products 
containing nanomaterials may improve our quality of 
life through more efficacious, targeted, pharmaceuticals, 
improved medical diagnosis tools, faster computers, 
clean water and cleaner energy production, to mention 
just some of the impending applications. It is also worth 
mentioning that nanomaterials can be used as research 
tools for investigation in laboratory settings and these 
are not intended for wider dissemination. The present 
report focuses on products to which consumers may be 
exposed.
Nanomaterials often display different chemical, physical 
and biological characteristics when compared with larger-
sized materials and thus behave differently, even when the 
elemental or molecular composition is the same. Some of 
their properties can be extrapolated from the macroscale, 
whereas other attributes change significantly below a 
certain size. Nanomaterials have a much larger specific 
surface or interface area, i.e. a larger area to mass ratio, 
than coarser materials. Furthermore, there are intrinsic 
nanoscale properties that result from the confinement 
of atoms and electrons within boundaries of a few 
nanometres. These effects are dominant at sizes below a 
few tens of nanometres and they can change fundamental 
physical material characteristics such as the optical, 
electrical and magnetic properties of the nanomaterial. 
For safety assessment it is important to take into account, 
as for any other chemical, potentially important other 
properties that may include surface charge, penetration 
ability, adhesion, solubility, immunogenicity, aggregation, 
shape, hardness, degradability, biopersistence, reactivity 
and other specific toxicities. Complexity of surface, 
multifunctionality of nanomaterials and covalent 
or adsorbed surface coatings all play a role in the 
determination of risk. Thus, it is important to address 
nanomaterial-specific considerations in the context 
of the general nanosafety objectives (environmental, 
occupational exposure and purposeful use).
In the following sections, we do not attempt a 
comprehensive description of all areas of application 
but focus primarily on consumer products and medical 
applications, two of the principal areas currently of interest 
to researchers and regulators.
3.1.1 Consumer products
Several of the consumer end-products available today 
that utilise nanomaterials have been developed from 
existing products, for example by the incorporation 
of nanomaterials into solid, viscous or liquid matrices. 
Examples of applications with end-products containing 
nanomaterials are listed in Box 3.1.
According to the Woodrow Wilson Nanotechnology 
Consumer Products Inventory (see Chapter 1), about one-
third of these products are sunscreen lotions or cosmetics 
such as skin-care and colorant products. 
For sunscreens, titanium dioxide and zinc oxide 
nanoparticles are used because they absorb and reflect 
ultraviolet rays but are still transparent to visible light: 
the resulting sunscreen becomes both more appealing 
to the consumer and is claimed to be more effective. 
Uncertainties about which cosmetic products already on 
the market actually contain nanomaterials led to questions 
about their safety41. 
41 Nohynek, G.J. et al., Skin Pharmacology and Physiology 21, 136 (2008).
OPPORTUNITIES AND SAFETY CONSIDERATIONS
Examples of consumer products that may contain 
nanomaterials 
Cosmetics and personal care products
Paints and coatings
Household products, e.g. for cleaning
Catalysts and lubricants
Sports products
Textiles
Food and nutrients
Food packaging and kitchenware
Consumer electronics
■
■
■
■
■
■
■
■
■
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In the food product sector, although there is not much 
knowledge about the occurrence of manufactured 
nanomaterials, a beneficial effect has been shown for 
food contact materials42. Further information is provided 
in the European Food Safety Authority (EFSA) report43. 
Nano-silver has many applications in many consumer 
products such as, for example, textiles making use of 
established antibacterial properties. A recent study has 
comprehensively investigated the challenges associated 
with human health risk assessment of nano-silver44.
The diversity of materials and products renders it a difficult 
task to ascertain how many ‘nano-products’ are on the 
market today. As discussed in Chapter 1, it is relevant to 
observe that the inclusion of products in the Woodrow 
Wilson database has been made on the producer’s claim 
that the product is a ‘nanoproduct’. Thus, the actual 
nanomaterials used within consumer products are not 
always known and, for the purpose of quantifying exposure 
assessment, it is also important to realise that information 
on the concentration of the nanomaterials in individual 
consumer products is generally not available11. If neither 
the identity nor the concentration of the nanomaterials 
used is known, it is not possible to take the safety aspects 
of nanomaterials into account. 
3.1.2 Medicine
Nanotechnology in medicine plays an important role 
in novel diagnostic and therapeutic approaches, drug 
delivery systems and tissue engineering. The use of 
nanoparticles in medicine is estimated to be the most 
rapidly expanding nanomaterial field of research45. This 
field is very broad: nanoparticles of many sizes, shapes, 
materials and structures with many core physico-chemical 
properties, and in many combinations with multiply 
structured coatings, are being investigated for diagnostic 
or therapeutic use. Intended routes of exposure include, 
for example, oral, intravenous, intranasal, vaginal, buccal 
and dermal. To cite just one example: an advanced area 
is the application of nanoparticles in cancer therapy, 
using gold nanorods, magnetic nanoparticles and carbon 
nanotubes to generate heat upon electromagnetic or 
infrared stimulation after direct injection into tumours or 
accumulation in tumours after systemic administration. 
Nanoparticle-mediated thermal therapy is a new and 
minimally invasive tool as a treatment of cancers46. This 
nanoparticle platform for thermal ablation of tumours can 
be combined with magnetic resonance imaging contrast 
agents to enhance simultaneous imaging modalities. 
Moreover, single-walled carbon nanotubes can be used 
as a novel contrast agent for non-invasive photo-acoustic 
imaging of tumours47. 
Another active area of research is leading to the 
development of drug delivery systems for cell-specific 
therapy by receptor-targeted nanocontainers. Of 
particular interest are injectable nanovehicles that are 
programmable towards specific targets, able to evade the 
immune defence, and sufficiently versatile to be suited as 
carriers of complex functionality.
Rather than attempting here to provide comprehensive 
discussion of the agents currently being tested in pre-
clinical and clinical research, the opportunities and 
challenges in the science and the issues for the regulatory 
framework in nanomedicine, key documents and activities 
are cited from previous European initiatives48; the work 
of the US National Nanotechnology Characterisation 
Laboratory cited in Chapter 2 is also highly relevant. 
42 Chaudhry, Q. et al., Food Additives & Contaminants A 25, 241 (2008).
43 European Food Safety Authority, EFSA Scientific Opinion, The potential risks arising from nanoscience and nanotechnologies on food and feed  
 safety, (2009).
44 Christensen, F. et al., Nanotoxicology 4, 284 (2010); Nowack, B. et al., Environmental Science & Technology 45, 1177 (2011).
45 Ben-Haim, N. et al., Nano Letters 8, 1368 (2008); Seigneuric, R. et al., Current Molecular Medicine 10, 640 (2010).
46 Krishnan, S. et al., International Journal of Hyperthermia 26, 775 (2010).
47 De la Zerda, A. et al., Nature Nanotechnology 3, 557 (2008).
48 European Science Foundation Forward Look on Nanomedicine 2005, followed by a series of research conferences and training events, accessible  
 on www.esf.org; JRC, Nanomedicine: Drivers for development and impact, 2006; European Technology Platform on Nanomedicine, accessible on  
 http:cordis.europa.eu/nanotechnology/nanomedicine.htm; European Commission Safety for Success Dialogue annual meetings, accessible on 
 http://ec.europa.eu/health/nanotechnology/events/ev_20110329_en.htm; EMA first Intern. Workshop on Nanomedicine Reg.: 
 http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2010/03/WC500075789.pdf; Duncan, R. and Gaspar, R., Nanomedicines under  
 the microscope, 2011, accessible on http://www.ruthduncan.co.uk/#/2011-nanomedicines-review/4551969069.
Box 3.2
The nanomaterials paradox: desired effects versus 
unexpected hazardous impact on health
The introduction of nanomaterials into clinical and other 
applications highlights the so-called ‘nanomaterial pa-
radox’: the very same properties that are desirable and 
potentially useful from a technological or biomedical 
perspective, such as the ability to cross biological bar-
riers and the high degree of surface reactivity, are also 
the properties that may give rise to unexpected and 
hazardous toxicities. It can be noted, however, that the 
nanomaterials paradox is not unique to nanomaterials 
or indeed to nanomedicine; for example the principle 
applies also to pharmaceuticals.
As a more general point, the nanomaterials paradox (Box 
3.2) is pertinent in raising issues for safety assessment of 
nanomaterials in consumer products.
All medical applications require careful evaluation of the 
biodistribution, biopersistence and biocompatibility of the 
administered nanomaterial. However, the fundamental 
challenge in nanomedicine as, indeed, in other applications 
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is how to modify nanomaterials so that the toxic effects are 
mitigated while preserving the unique and highly desirable 
properties of these materials. Of course, this challenge for 
developing novel healthcare approaches is not specific 
to nanomaterials and the regulatory framework for novel 
therapeutics routinely includes the study of side-effects in 
order to assure appropriate product safety. Furthermore, 
there is extensive experience in the pharmaceutical and 
biotechnology sectors for optimising the benefit–risk 
balance by assessing structure–activity relationships for 
series of chemically or biologically related candidates. 
The ‘quality by design’ approach with an integrated 
assessment of quality (including specification of product 
and reproducibility in manufacturing), safety and benefit, 
which is standard practice in the medical sector, provides 
an important model more generally for ‘safety by design’ 
for nanomaterials for other applications.
3.2 Safety aspects: overview on risk assessment 
methodologies and current results
As observed in Chapter 2, there is always a possibility that 
adverse effects will accompany the introduction of new 
technologies. Therefore the development and introduction 
of new materials and products must be accompanied by 
an appropriate risk-evaluation and risk-management 
process. For nanomaterials as for other materials, risk 
is a function of hazard and exposure; the general risk 
assessment paradigm7,49 comprises the following: 
Hazard identification, to understand which adverse 
effects are elicited.
Hazard characterisation, to determine the amount 
of nanomaterial needed to provoke a response (the 
dose–response function).
Exposure assessment, to understand the amount of 
the material to which consumers or the environment 
are exposed.
Hazard identification for nanomaterials is covered by the 
discipline of nanotoxicology; the toxicological aspects of 
nanomaterials are summarised in numerous publications, 
of which we cite only a few of the more recent50. Toxicity 
testing of engineered nanomaterials using in vitro or in 
vivo assays should aim to characterise a potential hazard 
by establishing the dose–response relationship. However, 
as the risk of adverse effects is a function of hazard and 
exposure, the assessment of the extent of possible 
exposure is essential if meaningful conclusions are to be 
generated. In this context it is important to appreciate that 
any nanomaterial administered at high enough doses will 
induce a significant ‘toxic’ effect. Therefore to be relevant, 
toxicity testing must identify which assays should be used, 
at which doses effects occur, and how realistic are these 
doses compared with human exposure conditions. Use of 
the dose–response approach also allows comparison of 
different nanomaterials and their comparison to reference 
substances of known properties. Well conducted dose–
response studies with the observation of no effect levels 
may give (with proper use of uncertainty/safety factors) 
some indication on exposure levels resulting in low or 
negligible harm. Even relatively harmless titanium dioxide 
nanoparticles given at high enough and repeated doses 
through inhalation have been demonstrated to induce 
lung tumours in rats due to lung overload51. More details 
can be found in Box 3.3. 
49 Walker, N.J. and Bucher, J.R., Toxicological Sciences 110, 251 (2009).
50 Shatkin, J.A. et al., Risk Analysis 30, 1680 (2010); Sharma, M., Indian Journal of Occupational and Environmental Medicine 14, 3 (2010); Clift, M.J.D. et  
 al., Archives of Toxicology, Epub ahead of print (2010); Krug, H. and Wick, P. Angewandte Chemie International Edition in English 50, 1260 (2011).
51 Bellmann, B. et al., Environmental Health Perspectives 97, 189 (1992); Benn, T. and Westerhoff, P., Environmental Science & Technology 42, 4133 
 (2008); Heinrich, U. et al., Inhalation Toxicology 7, 533 (1995); Ferin, J., et al., American Journal of Respiratory Cell and Molecular Biology 6, 535 (1992).
52 Roller, M., Inhalation Toxicology 21, Suppl. 1, 144 (2009).
53 Yokohira, M. et al., Toxicologic Pathology 36, 620 (2009).
54 Grieger, K.D. et al., Nanotoxicology 3, 1 (2009).
Most of the discussion of risk in this chapter refers to 
the risk of specific harm to human health. But there is 
another relevant aspect to the consideration of risk: the 
risk of not generating robust and relevant data, such that 
decision-making is poorly informed. Addressing both of 
these dimensions of risk requires the use of high quality 
procedures, for collecting data and for making regulatory 
judgements.
Performing risk assessment for engineered nanomaterials 
is a challenging task, not only because of scientific 
uncertainty and lack of data54, but also because of the 
■
■
■
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Box 3.3
Problems concerning unrealistic exposure doses
Overload conditions especially in the lung (macropha-
ges) have been described for 20 years. It is now well 
known that overloading the lung with dust particles 
will severely influence (reduce) the clearance process, 
thereby prolonging dramatically the biological lifetime 
of particles within the lung. Eventually, this leads to per-
sistent inflammatory effects with all the characteristics 
of lung diseases which often end in tumour formation.
Therefore, it is recommended that overload conditions 
should be avoided both in animal studies and for in vi-
tro experiments otherwise excessive doses will generate 
false-positive results. 
This sense of realism is equally warranted for intended 
applications where engineered nanomaterials are targe-
ted to the individual in relatively precise amounts. Mo-
reover, testing genotoxicity with overloading concentra-
tions (often cytotoxic concentrations) is also unrealistic 
as dying cells (apoptosis as well as necrosis) cleave their 
own DNA, resulting again in false-positive effects52. If 
non-overload conditions are chosen, no carcinogenic 
effects for such dust particles are found53.
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necessity of taking into account the wide range of different 
materials, their functional properties and applications55. 
Among the limitations often mentioned is the time-lag for 
an effect, and the associated costs to generate meaningful, 
quantitative results for risk assessments56. But again, 
this situation is not necessarily unique to nanomaterials, 
and the general limitations to chemical risk assessment 
procedures have been noted57. 
In the following sections, we provide an overview on 
exposure and hazard identification and characterisation 
for risk assessment of nanomaterials. We start by 
discussing the prerequisite for assessing exposure and 
potential hazard: the possible entry of nanomaterials into 
the human body and an understanding of interactions of 
nanomaterials with tissues and cells. 
Much of the research discussed in the following sections 
relates to the lung. This partly reflects the history of 
the field with its origins in a study of risk assessment 
for nanoparticles generated by combustion processes 
(ultrafine particles) but also takes account of the 
importance of the lung as portal of entry. 
3.2.1 Entry of nanomaterials into the human body and 
interaction with cells
3.2.1.1. Biological barriers
There are three portals of entry for nanoparticles in 
the human body: the skin, the gastro-intestinal tract 
and the lung although, of course, these portals can be 
circumvented by direct injection or implantation of a 
substance. The lung is a major portal of entry and has 
been relatively well-studied: analysis of this knowledge 
base provides guidance on the types of study that may 
be needed to characterise other portals of entry (see 
also Chapter 4). Over the huge alveolar surface area of 
150 m2 the deposited particles are separated from the 
capillary blood by a tissue barrier. This barrier is less than 1 
micrometre between the deposited particles and capillary 
blood58. Therefore, they may penetrate through the very 
thin tissue barrier into the blood with which they will 
be transported into secondary organs59. Nanoparticles 
may move through the tissue barriers in organs. Three 
critical structural parameters of the tissue barriers which 
are important for human health have to be taken into 
consideration: (1) the distance of blood capillaries; (2) 
the distance of sensitive cells, in particular cells of the 
defence system, from the location of deposition of the 
nanoparticles; and (3) the character and property of the 
barrier structures. In the lungs there is a particularly thin 
air–blood tissue barrier. The nanoparticles deposited on 
the alveolar surface of the lung come into closest vicinity 
with the blood and they have been shown to be able to 
cross the air–blood tissue barrier and to penetrate into the 
blood capillaries. When within the blood stream they can 
translocate to any other organ of the body60. Micrometre-
sized particles have never been observed crossing the 
air–blood tissue barrier and nothing is known yet about 
the mechanism as to how nanoparticles can cross this 
tissue barrier.
The blood–brain tissue barrier, although rather thin, 
has so far usually been considered impermeable except 
to some drugs. However, it has now been shown that 
nanosized gold particles have promising applications for 
therapeutic and diagnostic purposes and if their surface 
is appropriately modified they may penetrate from the 
blood into the brain61. This ability of certain nanoparticles 
to cross the blood–brain barrier could enable the delivery 
of therapeutic compounds to the brain62 but it also 
demonstrates the potential for side-effects. 
Another inner tissue barrier reached through the blood 
stream is the placental barrier63. It has recently been shown 
in an ex vivo study that nanosized fluorescent polystyrene 
particles were able to cross the placenta, i.e. to move 
from the maternal blood circulation into the foetal blood 
circulation. The blood–blood tissue barrier is rather thin 
and there is still a lot of research needed for the study of 
the nanotoxicological translocation from the mother to 
the child (see Chapter 4).
Many nanoparticles may enter the body and the blood 
circulation through the gastro-intestinal system. The tissue 
barrier between the surface and the blood capillaries is 
rather thick, 10–100 times thicker than the air–blood tissue 
barrier. Nevertheless, this is a common route of exposure 
for nanoparticulate matter which can be delivered in 
high concentrations over a surface area even larger than 
the lung, and nanoparticles may reach the capillaries in 
the connective tissue under the epithelial layer covering 
55 Maynard, AD. et al., Nature 444, 267 (2006); Owen, R. and Handy, R., Environmental Science & Technology 41, 5582 (2007); see footnote 26.
56 Choi, J., Environmental Science & Technology 43, 3030 (2009); Hansen, S.F., PhD thesis, Technical University of Denmark, 2009; Grieger, K. J., 
 Nanoparticle Research 12, 383 (2010).
57 Briggs, D.J., Environmental Health 7, 61 (2008): Kapustka, L., Integrated Environmental Assessment and Management 4, 290 (2008). 
58 Gehr, P. et al., Respiratory Physiology 32, 121 (1978).
59 Kreyling, W. et al., Journal of Toxicology and Environmental Health 65, 513 (2004).
60 Geiser, M. et al., Environmental Health Perspectives 113, 1555 (2005); Kreyling, W.G. et al., Journal of Toxicology and Environmental Health 65, 1513  
 (2002); Rothen-Rutishauser, B., et al., Interaction of particles with membranes. In: The Toxicology of Particles (eds K. Donaldson and P. Borm), 
 pp. 139–160, Taylor & Francis Group, CRC Press, Boca Raton, 2007; Rothen-Rutishauser, B. et al., American Journal of Respiratory Cell and  
 Molecular Biology 32, 281 (2005); Semmler-Behnke, M. et al., Small 4, 2108 (2008).
61 Guerrero, S. et al., Nanomedicine 5, 897 (2010).
62 Karatas, H. et al., Journal of Neuroscience 29, 13761 (2009).
63 Wick, P. et al., Environmental Health Perspectives 118, 432 (2010).
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the intestines which also leads to translocation into 
secondary organs. Some consider the gastro-intestinal 
tract as important for the uptake of nanoparticles as the 
lung and, of course, it plays an important role in the fate of 
nanocarriers after oral delivery64. The outer tissue barrier 
of the human organism, the skin, when intact, appears to 
be a rather tight barrier for all nanoparticulate material. Its 
surface area is rather small, about 1.5–2 m2, which is only 
about 1% of the alveolar surface area. 
Most of this surface area is rather impermeable for 
nanoparticles; there are only the hair follicles and the 
openings of the sweat glands available for particle 
penetration, but even these ‘weak’ locations are hardly 
crossed. It is suggested that titanium dioxide nanoparticles 
neither penetrate into viable cell layers nor cause any 
cellular changes65. The rather impermeable healthy 
and intact skin barrier may, however, be overcome by a 
combination of nanoparticulate drug carriers with protein 
drugs66; other issues for additional research, including the 
study of damaged skin, are discussed in Chapter 4.
3.2.1.2 Interaction with tissue and cells
The interaction of nanomaterials with cells can be regarded 
as a first step in the induction of possible health effects 
although it must also be appreciated that nanomaterials 
do not always have to be taken up by cells to exert effects. 
There are different hypotheses as to how nanomaterials 
are taken up by cells or how they enter cells67 but events 
always begin with the interaction of the nanomaterial 
with the cell membrane. 
Artificial organelles or nanoparticles may enter cells by a 
Trojan-horse-type mechanism68 and tailoring the lipoplex 
composition to the lipid composition of the cell membrane 
may enhance this Trojan-horse-like entry into cells69.
Moreover, only biopersistent engineered nanoparticles 
(ENP) maintain their ENP properties and according 
biological responses over retention time which are clearly 
distinct from readily soluble or moderately soluble ENP. 
Those ENP dissolving within days or a few weeks will lose 
their ENP properties such that the toxicologically relevant 
interactions of the dissolved metabolic constituents of 
the previous ENP determine the biological response. 
The kinetics of dissolution, for example in extracellular 
body fluids or intracellular compartments after 
endocytosis, is determined by an ENP-material-dependent 
dissolution rate constant and the specific surface area of 
the ENP and the biochemical properties of the dissolution 
solvent under the thermodynamic conditions of the living 
organism.
In summary, information on the multiple biological issues 
covered in this section 3.2.1 is crucial for a sound risk 
assessment of nanomaterials70. Moreover, to enable better 
comparison of studies performed in different laboratories, 
we emphasise that the concentrations used should be 
comparable and realistic, and materials must be well 
defined (see also Chapter 4). In particular, characterisation 
in terms of the mass concentration in a given experiment 
is often not adequate, as this does not reflect the real 
particle-to-cell ratio (see later sections and Box 3.5).
3.2.2  Exposure assessment
3.2.2.1 Exposure identification
Human exposure to nanomaterials can arise directly from 
the intended targeted delivery of product to individuals 
(for example in food, cosmetic and medical applications) 
and, indirectly, from the unintended exposure of workers 
during manufacturing and downstream use, and – for the 
general public – from nanomaterial accumulating in the 
environment. 
Exposure assessments must aim to summarise, both 
quantitatively and qualitatively, information on the 
duration, frequency, concentration and material of 
exposure of humans or the environment. Box 3.4 lists the 
categories of likeliness of consumer exposure in terms of 
product composition. However, it must also be emphasised 
that the products for which consumer exposure might be 
expected most frequently are in the category of products 
for which no information on the nanomaterial involved is 
available.
The first step in an environmental exposure assessment is 
the identification of exposure (see also Box 3.4). 
This means exploring the following:
Are there engineered nanomaterials present in the 
direct vicinity of people?
Can those be discriminated from the natural and 
anthropogenic background nanomaterials?
Can they be linked to a specific source or product?
64 Roger, E. et al., Nanomedicine 5, 287 (2010).
65 Adachi, K. et al., Nanotoxicology 4, 296 (2010); Butz, T. et al., Final Report of the project NANODERM (2007).
66 Huang, Y. et al., Biomaterials 31, 9086 (2010).
67 Krug, H. and Wick, P., Angewandte Chemie International Edition in English 50, 1260 (2011). Geiser, M. et al., see footnote 60; Rothen-Rutishauser, B.  
 et al., see footnote 60; Brandenberger, C. et al., Small 6, 1669 (2011); Blank, F. et al., American Journal of Respiratory Cell and Molecular Biology 36,  
 669 (2007).
68 Limbach, L.K. et al., Environmental Science & Technology 41, 4158 (2010).
69 Marchini, C., et al., Langmuir 26, 13867 (2010).
70 Borm P.J. et al., Particle Fibre Toxicology 3, (2006); Krug, H. (Ed) ‘Nanotechnology – Volume 2: Environmental Aspects’, Wiley-VCH, Weinheim, 2008,  
 pp. 328; Abbott, L.C. and Maynard, A.D., Risk Analysis 30, 1634 (2010). 
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As discussed previously (Chapter 1), it must also be 
emphasised that unintended exposures might arise from 
the manipulation of previously embedded nanomaterials 
(e.g. in composite products). 
Exposure studies at work places or relating to specific 
consumer products may be easier to conduct than those 
aiming to identify exposure for the general public. In the 
former cases the type of nanomaterial, its chemistry and 
morphology, is mostly known and the concentration can 
be expected to be elevated above background. In the latter 
case, possible exposure of the population, concentrations 
can be expected to be significantly lower and the matrix 
in which the nanomaterial is embedded or attached 
to may be more complex. Furthermore, nanomaterials 
released into the environment usually undergo changes 
during their transmission, making it barely impossible 
to differentiate them from non-engineered materials of 
the same size. Therefore, at workplaces specific exposure 
identification strategies are recommended to be applied 
and pursued on a regular basis. But although these may 
represent feasible strategies for workplaces, they cannot 
be applied in the same way to indicate exposure for the 
public. Here, new strategies have to be developed and 
deployed.
3.2.2.2 Exposure routes
Most studies so far have focused on nanoparticle exposure 
through inhalation or through the skin, as these are the 
two main exposure routes in the occupational setting 
(see preceding section). Although the latter has been 
shown to be a good barrier for nanomaterials, uptake 
of airborne nanomaterials by inhalation is quite likely. 
In addition, systemic administration will be evaluated 
for nanoparticles that are intended for clinical use and 
application of nanomaterials in the food sector including 
food packaging materials. The latter may lead to exposure 
through the gastro-intestinal tract. 
Quantitative information on the uptake through the 
gastro-intestinal tract is still sparse.
  
As described previously, once nanomaterials have 
overcome the biological barriers associated with the 
portals of entry, it is important to consider that the 
particles may travel to other distant organs. Moreover, in 
addition to the major route of transportation in the blood, 
studies in animal models have shown that inhalation of 
certain nanoparticles may result in uptake through the 
olfactory nerve in the area of the olfactory epithelium 
with subsequent translocation of nanoparticles into the 
central nervous system through the olfactory nerves71. It 
is crucial to take into account particle-specific phenomena 
when assessing the hazard of engineered nanomaterials. 
3.2.2.3 Exposure characterisation
The characterisation of exposure may also include studies 
related to nanomaterial release and the behaviour and 
mobility in the environment since this significantly 
influences the probability of exposure. While workplace 
exposure data become more common72, very few 
published studies describe consumer or environmental 
exposures to nanomaterials, even for the most abundant 
particle types. Most current studies for exposure 
assessment are either stationary measurements allowing 
detailed analysis of nanoscale particles in the environment 
or using explorative personal samplers which cannot 
discriminate between engineered, by-products or natural 
nanoscale particles. 
3.2.2.4 Exposure assessment
Among the key questions related to exposure assessment 
are the following:
 
How can we effectively discriminate ambient from 
engineered nanoscale particles/ objects?
How reliable are current measurement results?
What metric shall be used for exposure assessment 
(see also Box 3.5)?
Is standardisation needed? If yes, what exactly shall 
be standardised?
How can particle morphology and other alternative 
information be assessed?
For the future, it is vital to integrate detailed knowledge 
from personal samplers for exposure assessment, work 
place monitors and tests of release probabilities from 
consumer products, into a comprehensive usable 
exposure assessment and safety design73. 
71 Oberdörster, E., Environmental Health Perspectives 112, 1058 (2004).
72 Brouwer, D., Toxicology 269, 120 (2010).
73 Azong-Wara, N. et al., Journal of Nanoparticle Research 11, 1611 (2009); Kuhlbusch, T.A.J. and Fissan, H., Journal of Occupational and 
 Environmental Hygiene 3, 558 (2006); Kuhlbusch, T.A.J. et al., Journal of Occupational and Environmental Hygiene 1, 660 (2004); 
 Vorbau, M. et al., Journal of Aerosol Science 40, 209 ( 2009).
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Box 3.4
Categories for consumer exposure through products
Using knowledge on the location of the nanomaterial 
within the products, they may be divided into three ca-
tegories, depending on the physical state (see Box 1.2):
Expected to cause consumer exposure (relevant for 
categories ‘nanoparticles suspended in liquids’ and 
‘airborne nanoparticles’).
May cause consumer exposure (relevant for the 
category ‘surface-bound nanoparticles’).
No expected exposure to the consumer (relevant for 
category ‘nanoparticles suspended in solids’). 
■
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Box 3.5
3.2.2.5 Exposure scenarios
Workers
For workers, an exposure to nanomaterials may occur 
if these materials are released to the environment, for 
example by combustion and or shear forces in the solid, 
liquid or gas phase (e.g. by spraying). The study 
of agglomerate stability in the airborne phase77 is 
particularly important. The different methods used in 
these studies cover a wide range of the shear forces to 
which nanomaterials may be exposed and the results 
can be used for ranking of particle release for different 
nanomaterials as well as functioning as an input parameter 
for different workplace processes. The first workplace-
related study differentiating ambient nanoscale particles 
from engineered nanoparticles was performed in the 
carbon black production industry78. The finding that 
sources other than those associated with the handling of 
nanomaterials may significantly contribute to measured 
particle concentrations is now common knowledge. 
Still, clear identification of exposures and the sources is 
currently a difficult task. 
Consumers
As mentioned above, the assessment of consumer 
exposure to nanomaterials is difficult and complex, and 
at a stage of early development. Even though consumers 
may be directly exposed to nanomaterials through 
consumer products, especially cosmetics, drugs and 
other applications, there are considerable uncertainties 
about the exposure dose for some of these applications 
(cosmetics) although perhaps not others (medicines). 
For those products containing nanomaterials that are 
already on the market, there are no indications so far 
that these materials cause specific health problems but it 
is generally agreed that more work needs to be done79. 
Owing to the (current) difficulties in direct measurements 
and monitoring of consumers, a focus should be set on 
investigations studying release of nanomaterials from 
products. To reiterate a previous point, it is also critically 
important to consider the benefit–risk balance: toxicity 
issues may be regarded rather differently if the product 
is delivering substantial benefit, for example in cancer 
thermo- and chemotherapy.
Environment
The number of ecotoxicological studies of engineered 
nanomaterials has rapidly increased in the past few 
years80. However, the data obtained so far are somewhat 
inconsistent and not sufficiently systematic to allow 
an overview of the potential environmental hazards 
relating to engineered nanomaterials. The increasing 
use and production of nanomaterials leads to multiple 
potential points of entry resulting in environmental 
exposure, including the traditional exposure routes 
for assessment of conventional chemicals, for example 
production wastes (liquid, solid, airborne), release from 
products during the product life, and during the waste 
cycle. In terms of exposure to the aquatic environment, 
the widespread and diverse use of consumer products 
74 Abbott, L.C. and Maynard, A.D., Risk Analysis 30, 1634 (2010); Brouwer, D. et al., Journal of Nanoparticle Research 11, 1867 (2009); Fissan, H.S. et al.,  
 Journal of Nanoparticle Research 9, 53 (2007); Oberdörster, G., Philosophical Transactions of the Royal Society of London A 358, 2719 (2000).
75 Rushton, E.K. et al., Journal of Toxicology and Environmental Health A 73, 445 (2010).
76 Krug, H. and Wick, P, Angewandte Chemie International Edition in English 50, 1260 (2011).
77 Bach, S. and Schmidt, E., Annals of Occupational and Environmental Hygiene 52, 717 (2008); Kuhlbusch, T. et al. (eds), ‘NanoCare: health related  
 aspects of nanomaterials’, DECHEMA e.V. (2009); Schneider, T. and Jensen, K.A., Annals of Occupational and Environmental Hygiene 52, 23 (2008); 
 Stahlmecke, B. et al., Journal of Nanoparticle Research 11, 1625 (2009).
78 Kuhlbusch, T.A.J. et al., J. Occupational and Environmental Hygiene 1, 660 (2004); See Kuhlbusch and Fissan in footnote 73.
79 Borm, P.J. et al., International Journal of Cancer 110, 3 (2004); Fryzek, J.P. et al., Journal of Occupational & Environmental Medicine 45, 400 (2003); 
 Gardiner, K. et al., Annals of Occupational Hygiene 36, 477 (1992); Hext, P.M. et al., Annals of Occupational Hygiene 49, 461 (2005); Merget, R. et al.,  
 Archives of Toxicology 75, 625 (2002).
80 Baun, A. et al., J. Environ. Monit 11, 1774 (2009); Farré, M. et al., Environmental Science & Technology 43, 9216 (2009); Gottschalk, F. et al., 
 Environmental Toxicology and Chemistry 29, 1036 (2010); Kahru, A. and Dubourguier, H.C., Toxicology 269, 105 (2010); Klaine, S.J. et al., 
 Environmental Toxicology and Chemistry 27, 1825 (2008); Mueller, N.C. and Nowack, B., Environmental Science & Technology 42, 4447 (2008); Stone,  
 V. et al., Final Report of FP7 Coordination and Support Action. Grant Agreement number: 218433; Stone, V. et al., Science of the Total Environment  
 408, 1745 (2010).
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Dose-metrics for in vivo and in vitro studies
One further obstacle to overcome in the near future is 
the choice of preferred metrics of exposure and treat-
ment concentrations. Mass concentrations are currently 
seen as too insensitive a metric and possibly not really 
relevant for nanospecific health effects. Other metrics 
currently discussed for exposure concentrations are par-
ticle surface area and particle number concentrations74. 
It is important that proposed measurement techniques 
are feasible in widespread practice.
Once agreement on the best exposure metric is reached, 
a congruent dataset relating the exposure to health ef-
fects will have to be developed. The same challenge ap-
plies to experimental studies in vivo and in vitro. So far 
there is no consensus on metrics, but the specific surface 
area was suggested as the best choice for in vivo expe-
riments75. For in vitro experiments it was demonstrated 
that mass concentrations given as mass per volume are 
correlated poorly with the outcome, and as experimental 
conditions are often different (cell number per dish and 
surface area; amount of medium above cells) the effects 
differ strongly even when the same mass concentrations 
has been used. Thus, it was suggested to calculate results 
in terms of more than one dose or concentration metric 
for each of these experiments, which could include (1) 
mass per volume, (2) mass per surface area, (3) number 
of particles per cell and (4) mass per cell76.
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87 Adelmann, M.D. et al., In: Toxic and carcinogenic effects of solid particles in the respiratory tract. ILSI Press, Washington, DC, 1994, pp. 405.
88 Mögel, I. et al., Toxicology Letters 96, 25 (1998); Wottrich, R. et al., International Journal of Hygiene and Environmental Health 207, 353 (2004); Geiser  
 et al., see footnote 60; Rothen-Rutishauser et al., see footnote 60; Blank et al., see footnote 67; Mühlfeld, C. et al., American Journal of Physiology –  
 Lung Cellular and Molecular Physiology 294, 817 (2008); Brandenberger, C. et al, Toxicology and Applied Pharmacology 292, 56 (2009); Lehmann, A.  
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containing engineered nanomaterials makes municipal 
wastewater an area of specific concern81, because several 
studies have demonstrated a release of engineered 
nanomaterials incorporated in textiles and paints to the 
aquatic environment82. A significant fraction of engineered 
nanoparticles were found to escape the clearing system 
of the wastewater plant, demonstrating the complex 
interactions between dissolved species and nanoparticles 
within the continuously changing environment of the 
clearing sludge83.
Bioaccumulation of nanomaterials in environmental 
species may, in theory, be a route for human exposure 
similar to that previously found for numerous 
persistent organic pollutants and metals. However, it 
remains unknown whether this is indeed a significant 
exposure route for nanomaterials because the number 
of studies dealing with this issue is still too limited.
3.2.3 Hazard assessment 
Epidemiological studies have revealed that pollution by 
ambient particulates is associated with respiratory and 
cardiovascular diseases, particularly in the elderly and 
in patients with pre-existing cardiopulmonary diseases. 
Moreover, there is evidence that ambient particulate 
matter can act as an adjuvant for allergic sensitisation, 
which raises the possibility that long-term particulate 
matter exposure may lead to increased prevalence of 
asthma84. 
As this is often dependent on the mixture of substances 
and materials comprising the particulate matter, a detailed 
understanding of the physico-chemical properties of 
engineered nanomaterials is required to predict their 
possible interaction and/or interference with biological 
systems. 
This lesson has been ingrained into researchers in the field 
of nanosafety over the past few years and it is important 
to use well-characterised and described nanomaterials in 
toxicology studies. An overview of the knowledge gained 
by studies on particulate matters from the environment is 
given in Box 3.6.
Box 3.6
Historical case studies on combustion-derived  
particulate matter
Stimulated by ongoing discussion about the fine dust 
problem within the environment, and the health-related 
consequences of ultrafine particles released by fossil 
fuel and wood combustion, it was a logical extension to  
cover synthetic or engineered nanoparticles. Many of the 
experts in the topic of nanotoxicology started their rese-
arch on ultrafine dust and lung damage. Early studies, 
in the 1990s compared the toxic effects of environmen-
tally relevant ultrafine particles with ultrafine titanium  
dioxide85. In 1990 a first paper was published on synthe-
tic particles and their effects on primary lung macropha-
ges86 with, some years later, a publication about fullere-
ne toxicity87. 
For the first time a multicellular three-dimensional in  
vitro model was developed for the lung which was used 
for nanoparticle research and optimised during the past 
5 years88. The research on particle–lung interactions  
started as early as the 1980s with one of the first papers 
on so-called submicron-particles89. 
Thus, the possible health effects of ultrafine particles 
have been investigated long before the consideration 
of the possible risks of nanoparticles, and the methodo-
logical advances that were achieved are relevant for the 
assessment of engineered nanomaterials. It is important 
to fill the knowledge gaps for the specific health aspects 
related to the uptake, distribution, possible accumula-
tion and biological effects in secondary organs induced 
by nanoparticles (see Chapter 4). It is also important 
to appreciate, however, as discussed elsewhere in this  
report, that the deliberate targeting of new generations 
of well-defined engineered materials in specific amounts 
– direct exposure – will stimulate new thinking on those 
aspects of risk assessment and risk management that, 
hitherto, have been based on experience of indirect  
exposure.
3.2.3.1 Hazard identification
Hazard identification aims to identify causality between 
inherent physical and chemical properties and observed 
adverse effects. This structure–toxicity type of approach 
has much to commend it but is proving as difficult in 
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nanotoxicology as in conventional particle toxicology. 
It is useful to discriminate between different hazards90:
hazard at sites of deposition;
hazard resulting from translocation (which then 
gives rise to a hazard at the new site of deposition 
where translocation deposits the particles) or from 
transmission of a response from one target site to 
another (e.g. mediated by cytokines).
Hazard identification for effects at sites of deposition
The lung shows very clear size-dependent pro-
inflammatory effects of low toxicity nanomaterials. It is 
important to understand that some nanoparticles may 
have high surface reactivity and the factors that induce 
surface high reactivity include charge, free radical activity 
and general chemical reactivity. Quartz is a good example 
of a particle that has high surface reactivity in the form 
of reactive groups and free radicals91. It was suggested 
that surface free radical activity measured in several assay 
systems in vitro is an attribute that predicts inflammatory 
potential75. If surface area and surface reactivity together 
drive the inflammatory response to insoluble particles, 
then it seems clear that any nanomaterials possessing 
high surface reactivity would be highly inflammatory 
because the total area of reactive surface would be high. 
Shape may also be an important characteristic in the case 
of long thin or fibrous nanoparticles, otherwise defined as 
high aspect ratio nanoparticles. The case of asbestos has 
drawn attention to the extra hazard of the pleura from 
long, biopersistent fibres, and various types of nanofibre 
are available (e.g. carbon nanotubes) that appear to show 
some of the properties of harmful asbestos92.
Translocation hazard
Translocation away from site of deposition has been 
considered to be one of the defining properties of 
engineered nanomaterials, a consequence of their small 
size. Although it may seem intuitively likely that small size 
would be associated with the property of translocation 
from, for example, the lungs, there is no evidence for 
this in humans, although there is in rodents93. In rats, it 
has been shown that translocation away from the lung 
is more efficient for smaller nanomaterials in the case of 
radioactive iridium (20 nm compared with 80 nm)94. Care 
must be taken in the interpretation of translocation studies 
■
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for soluble nanomaterials, because soluble ions might be 
the translocated entity. Although small nanomaterials 
might be more readily translocated it is, as in all toxicology, 
the extent of the translocated dose that will determine 
any effects at targets remote from the portal of entry. 
There are usually insufficient data available from 
toxicokinetics to ascertain whether there may be sufficient 
dose reaching the extra-pulmonary organs to elicit a 
response. What is clear is that there can be effects at extra-
pulmonary sites as a consequence of inflammatory signals 
emanating from the lungs95.
In summary, there is good hazard identification for the 
relationship between structure and toxicity for low-
toxicity engineered nanomaterials: namely surface 
area is the driver of inflammation at sites of deposition. 
However, surface reactivity and solubility and the other 
characteristics of nanomaterials, listed in section 3.1, are 
not well understood in their capacity as modifiers of small 
size in the translocation dose–response curve. 
3.2.3.2. Hazard characterisation
Taking the data on the lung, because it is a well-
characterised organ, it can be summarised that hazard 
characterisation of nanomaterials draws on various 
sources:
Literature on ultrafine particles/particulate matters 
epidemiology/toxicology (as listed in Box 3.6).
Literature on rat lung overload e.g. using ultrafine 
titanium dioxide, carbon black (as listed in Box 3.3 
and 3.5). 
Literature on animal studies with nanomaterials, 
although there are not many of these: carbon 
nanotubes have been examined extensively and 
cause rapid inflammation and fibrosis at low to 
moderate lung burdens96. Other studies suggest that 
some metallic engineered nanomaterials can cause 
immunopathology by delayed hypersensitivity 
mechanism but this is by instillation97.
Literature on human exposures to nanomaterials98. 
Literature on conventional particle toxicology (see 
also Box 3.7): the occupational exposure paradigm 
is high levels of exposure in relative healthy males 
producing fibrosis (e.g. quartz) and cancer (e.g. 
asbestos). 
91 Duffin, R., Inhalation Toxicology 19, 849 (2007).
92 Donaldson, K. et al., Particle Fibre Toxicology 7, 5 (2010).
93 Nemmar, A. et al., Circulation 105, 411 (2002); Mills, N.L. et al., American Journal of Respiratory and Critical Care Medicine 173, 426 (2006).
94 Kreyling, W.G., Inhalation Toxicology 21, 55 (2009).
95 Van Eeden, S.F. and Hogg, J.C., Journal of Toxicology and Environmental Health A 65, 1597 (2002); Kagan, V.E. et al., Nature Nanotechnology 5, 
 354 (2010).
96 Shvedova A.A. et al., American Journal of Physiology - Lung Cellular and Molecular Physiology 295, L552 ( 2008); Pauluhn, J., Toxicological Sciences  
 113, 226 (2010); Ma-Hock L. et al., Toxicological Sciences 112, 468 (2009; De la Zerda, A. et al., Nature Nanotechnology 3, 557 (2008); Park, J.-H. et al.,  
 Nature Materials 8, 331 (2009).
97 Cho, W.S. et al., Environmental Health Perspectives 118, 1699 (2010); Yokohira, M. et al., Journal of Toxicologic Pathology 22, 1 (2009).
98 Davis, M.E. et al., Nature 464, 1067 (2010); Powell, J.J. et al., Journal of Autoimmunity 34, J226 (2010).
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These sources vary in the amount of relevant information 
they offer for hazard identification of engineered 
nanomaterials in the lung. Taken together, the literature 
suggests that potential hazards of nanomaterials 
may include several pathobiological processes 
such as cytotoxicity, oxidative stress, inflammation, 
genotoxicity and sensitisation that might lead to 
diseases such as fibrosis, cancer, bronchitis, alveolitis, and 
immunopathology (e.g. asthma). In addition, the hazard 
associated with translocation from the pulmonary portal 
of entry to the blood, or the systemic consequences of 
inflammation/oxidative stress in the lungs, could in theory 
result in neurophysiological effects, cardiovascular effects 
(atherothrombosis, cardiotoxicity) and foetal damage/
abnormality among other consequences (see Box 3.7).
As described in Chapter 4, it is important to develop a 
comparable knowledge base for other routes of exposure, 
using the knowledge base on the lung as a model for what 
can be achieved.
3.2.3.3. Hazard assessment
For the testing of biological effects by nanomaterials, 
an international working group of the International Life 
Sciences Institute suggested a tiered approach99:
physico-chemical characterisation;
cell-free assays (solubility; reactive oxygen 
species-generating potential; chemical reactivity; 
agglomeration ⁄ aggregation; zeta potential; other 
properties);
in vitro assays (primary cells; cell-lines; primary and 
secondary organs; co-cultures);
in vivo assays (generally rodents; diverse 
methodologies: respiratory tract, skin, 
gastrointestinal tract).
A primary question to be answered is whether any of the 
in vitro tests used would be able to predict in vivo toxicity. 
However, this question again is not specific for studies with 
nanomaterials. Some studies were designed to determine 
 Aspects of conventional particle toxicology 
 Pathobiological processes:   Cytotoxicity, oxidative stress, inflammation, 
      genotoxicity, sensitisation, immunotoxicity
 Diseases at lung portal of entry:  Fibrosis, cancer, bronchitis, alveolitis, 
      immuno-pathology, mesothelioma (other pleural effects)
 Extra-pulmonary effects following   Atherogenesis, plaque rupture, cardiotoxicity, foetal effects,
 lung exposure:    brain neurotoxicity
whether in vitro assays are predictive for in vivo effects100. 
Further results are available from the NanoCare project 
funded by the German Government101. This consortium 
demonstrated that there is good correlation between 
the results obtained from experiments with primary lung 
macrophages and in vivo studies. For the future, it can 
be expected that there will be rapid advances in new 
testing procedures that can be applied to nanomaterials-
drawing on substantial progress in introducing platform 
technologies for high-throughput safety screening, use 
of proteomics, metabolomics and other ‘omic’-based 
measurements and the use of ‘humanised’ cell systems. 
There will also be increasing opportunities to feedback 
information, for example on relevant biomarkers as clinical 
correlates, from studies in humans and experimental 
animals, to improve predictive tests. One other lesson 
that must be learnt from clinical medicine is that safety 
responses can be influenced by individual variation in 
genotype and phenotype.
In summary, testing of nanomaterials is far from being 
standardised and many previous studies are not capable 
of being directly compared, although differences 
can be informative if investigated in sufficient detail. 
Furthermore, exposure data are only rarely available 
and there are many remaining questions about the risk 
assessment of engineered nanomaterials. We recognise 
that much of the research reviewed in this chapter 
relates to lung exposure; this reflects the twin origins of 
the nanosafety field in exploring unintended exposure 
through inhalation to environmental pollution and in the 
occupational health agenda for employee protection. We 
emphasise that research priorities are rapidly emerging 
for the broader field of enquiry that covers the safety 
of intended exposure to engineered nanomaterials by 
various routes. In Chapter 4 we identify the priorities 
for filling the gaps in knowledge that will begin to 
answer many of the questions. However, it is worth also 
emphasising again that the safety assessment procedures 
used for nanomaterials in established product sectors 
such as medicine can be expected to be very similar to 
the procedures already developed and validated by those 
sectors for assessing innovation from any other source. 
  99 Oberdörster, G. et al., Particle Fibre Toxicology 2, 8 ( 2005).
100 Seagrave, J. et al., Journal of Toxicology and Environmental Health 66, 1113 (2002); Sayes, C.M. et al., Nano Letters 7, 2399 (2007).
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4 Filling the Gaps
In the previous chapters, examples were selected from 
current knowledge as the basis for identifying what types 
of further effort will be required to understand the health 
impacts of nanomaterials. This extra research effort has 
to span the continuum from basic, through translational, 
to applied research. It must be multidisciplinary and 
connected by validation, standardisation, regulation and 
innovation, to industry and other users of research, in 
pursuit of societal objectives.
Clearly, any successful application of the risk assessment 
within the broader context of establishing the benefit–
risk balance requires better information about which 
nanospecific features need to be taken into account (see also 
section 3.1). Although a modification of the dose–response 
relationship might reasonably be expected in association 
with decreasing particle size, it could be interpreted, 
variously, in terms of biological distribution, surface effects, 
increased solubility or other attributes, as discussed in 
Chapter 3. The current evidence is rarely sufficient to 
distinguish between the different possible explanations. 
Nonetheless, in the absence of this definitive evidence, a 
precautionary approach to nanomaterials102, consistent 
with the procedures involved in REACH regulation and 
adopted in the action plans of governments and industrial 
associations, seems to have been successful so far 
in preventing major problems although it should be 
recognised that in some cases there may not have been 
sufficient exposure over longer time periods to allow 
chronic effects to be ruled out. 
Can this successful governance continue into a future 
where the number of applications and extent of industrial 
production rapidly grow? We judge that it can, but it 
requires the joint efforts of academia, industry and 
public policy-makers to incorporate safety-by-design, to 
understand both the acute and longer-term biological 
responses, and to ensure that production and downstream 
handling entail good working practices. 
In the following sections, we provide detail on our 
recommendations for the support both of basic research 
to fill gaps in fundamental knowledge, and the translation 
of that knowledge more effectively in product and policy 
development. 
In the space available we cannot provide detail on 
the entire research agenda. Rather, we again provide 
examples to represent and illustrate the different types of 
investigation required. 
We believe that it is also increasingly possible to maximise 
the value of that knowledge already available by 
capitalising on new opportunities for meta-analysis and 
modelling.
4.1 Basic science
We advise that the funding strategies of the EU and its 
Member States should be better co-ordinated in order to 
identify and resolve the strategic research questions and 
methodological developments. We recommend particular 
attention to the following topics.
4.1.1 Relevant dose
To reiterate our previous point, research projects often 
study safety responses at very high doses and this may 
not always be relevant to likely exposure. There is much 
more to be done to establish realistic dose–responses, 
over long-term dosing where necessary, using well-
defined materials. Consideration of appropriate dose is 
also particularly important in devising animal experiments 
in order to limit animal use, although studies in vitro can 
allow expansion of doses considered. In vitro models are 
currently particularly useful for screening and mechanistic 
studies but, in many cases, need further validation before 
being usable for risk assessment. 
There are additional challenges in assessing dose–
responses relating to (1) the ability of some nanoparticles 
to deliver high concentrations at the local, cellular, 
level because of dissolution or expression of surface 
reactivity, and (2) consideration of potential differences 
in individual susceptibility arising from, for example, 
genetic disposition, age and disease. The importance of 
standardisation in experiments, both to generate valid 
data and to allow the more systematic aggregation of 
findings from different laboratories, has been emphasised 
in Chapter 3; in this context it is also vital to pay attention 
to potential differences in quality between different 
production batches of nanomaterials.
4.1.2 Cellular level
There are many gaps in the understanding of how 
nanoparticles interact with cell membranes, are 
transported and behave inside cells. Among the 
102 Hoeck, J. et al., Instructions concernant l’usage d’une grille de précaution pour les nanomatériaux synthétiques, Office Fédéral de la Santé 
 Publique (OFSP) et Office Fédéral de l’Environnement (OFEV), Berne 2010.
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fundamental questions to be answered by further research 
are the following.
How do nanoparticles enter mitochondria and 
interact with the respiratory chain?
In what circumstances do nanoparticles enter 
the nucleus and interact directly or indirectly 
with DNA? Might genetic variation or epigenetic 
changes103 modify the response? Are nanoparticles 
more genotoxic than larger particles of the same 
materia104? 
How do nanoparticles interact with other cellular 
organelles such as lysosomes and could this interfere 
with lysosomal chemistry and function? Initial 
studies105 suggest that some nanoparticles localise 
in lysosomes, triggering lysosomal cell death. 
Production of cytokines and chemokines may be 
triggered. Oxidative stress and pro-inflammatory 
reactions may follow. Also, the inflammasome may 
be activated106. It should be stressed, however, that 
these reactions and pathways are not unique to 
nanoparticles. Responses may also depend on the 
type and amount of impurities potentially present in 
the particles. 
To what extent can nanoparticles induce indirect 
effects on cells, across a biological barrier, for 
example through transmission of purine nucleotides 
and intracellular signalling through gap junctions107?
What are the nanoparticle properties that mediate 
cellular responses? Smallness, surface reactivity and 
solubility could all be determinants of nanoparticle 
translocation and dose-dependent toxicity (see 
Chapter 3). More research is required to identify the 
specific physico-chemical features that are associated 
with biological behaviour of nanoparticles at the 
cellular level. There are concomitant questions for 
fundamental research on the consequences of these 
features: for example, could interference with protein 
folding108 be a problem?
4.1.3 Organ level
As described in Chapter 3, nanosafety assessment has 
its origins in the study of particle–lung interactions and 
this remains a significant research topic. Beyond the lung, 
there are many gaps in knowledge about the health 
impacts relating to uptake, distribution, accumulation 
and biological consequences in secondary organs 
after inhalation. The responses to the other routes 
of administration intended for some nanomaterial 
applications are also relatively poorly characterised. It is 
uncertain which nanoparticles can cross the blood–brain 
barrier although current evidence suggests that any 
such transfer is small109. It is also not clear if some 
nanoparticles can cross the barrier between blood and 
testes or ovary, or between the blood and the thymus 
tissue, for example: if they can, there will be a significant 
research agenda for reproductive toxicology and 
immune toxicology. The maternal–foetal translocation 
of nanoparticles is possible110 (see also Chapter 3), which 
raises the possibility of developmental effects.
It is conceivable that effects demonstrated in one organ 
will have implications elsewhere but there are still many 
knowledge gaps. For example, in air pollution research, 
deposited reactive particles have been proposed to cause 
oxidative stress in the lungs (Chapter 3) and the resultant 
pro-inflammatory response in the lung endothelium 
might be transmitted to organs susceptible to the effects 
of thrombosis and atherosclerosis111. 
Nanoparticles might also be deposited directly in 
atherosclerotic plaques but their propensity to contribute 
locally to inflammation is unknown. This knowledge gap 
might be filled by collaboration with the manufacturers of 
radiological contrast material that consists of nanoparticles 
to visualise organ systems. 
4.1.4 Immune system
The immune system is designed to protect against all 
forms of foreign intrusion, not only micro-organisms 
but also particles112. Recent research, including the 
Framework Programme 7 project Nanommune113, is 
beginning to provide a comprehensive evaluation of 
the influence of nanoparticles on the immune system114. 
However, more research is warranted in models of disease 
susceptibility to understand if an increased risk is posed 
in certain populations, for example those with infection 
or asthma.
103 Riediker, M. et al., In: Towards Predicting Nano-Biointeractions: An International Assessment of Nanotechnology Environment, Health and Safety  
 Research Needs, Vol. 4. Rice University, Houston, Texas, 2008 pp. 2-62.
104 Papageorgiou, I. et al., Biomaterials 28, 2946 (2007).
105 Shapero, K. et al., Molecular BioSystems 7, 371 (2011).
106 Tschopp, J. et al., Nature Reviews Immunology 10, 210 (2010).
107 Bhabra, G. et al., Nature Nanotechnology 4, 876 (2009).
108 Linse, S. et al., Proceedings of the National Academy of Sciences of the USA 104, 8691 (2007).
109 Oberdörster, G. et al., Inhalation Toxicology 16, 437 (2004).
110 Yamashita, K. et al., Nature Nanotechnology 6, 321 (2011); Myllynen, P.K. et al., Reproductive Toxicology 26, 130 (2008).
111 Brook, R.D. et al., Circulation 121, 2331 (2010).
112 Shvedova A.A. et al., see footnote 96.
113 FP 7 Project Nanommune: www.nanommune.eu.
114 Konduru N.V. et al., PLoS One 4, e4398 (2009).
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An important concept may be emerging from the 
potential for accretion of a biomolecular corona around 
nanoparticles: the addition of a coat of protein or lipids 
in the biological environment115. This surface coating may 
determine interaction and biological effects. Does the 
immune system respond to the naked nanoparticle or 
the corona? Could the nano-bio-interface be modified to 
mitigate any toxicity response, while retaining the desired 
properties of nanoparticles?
4.2 Exposure
Several peer-reviewed studies related to workplace 
measurements and possible nanomaterial exposure can 
be found in literature75. The European NANEX project116 
found rather little published information on acute or 
chronic exposure. Both investigations clearly showed the 
inadequate comparability of the studies and their results. 
Owing to the limit of validated and comparable 
information, exposure scenarios and risk assessments can 
only be set up with relative high uncertainty. In the few 
comprehensive databases, all built on country-level (e.g. 
Switzerland and USA117), data on occupational exposure 
were collected, but the potential for consumer exposure 
was not addressed. 
As noted earlier in our report, in many applications, 
nanomaterials are closely embedded in macro-structures, 
for example in the electronics, IT, transport and space 
sectors. In such cases, engineered nanomaterials are likely 
to pose low risk for consumer exposure and environmental 
risk during their lifetime embedded in the larger structures 
but then there is need to take account in lifecycle analysis 
of the potential later consequences of manipulating the 
embedded product (see Chapters 1 and 3). In contrast, 
nanomaterials in food applications, paints and coatings, 
cosmetics, textiles and healthcare products may lead to 
substantial early exposure. 
Risk management requires assessment based on realistic 
exposure scenarios in well identified groups. In our view, 
the major gaps that need to be filled in assessing exposure 
are the following.
4.2.1 Use, production and disposal
In the country survey mentioned above, about 1% of 
Swiss companies reported the presence of nanoparticles 
but none of these companies was a primary producer. 
Thus, in addition to clarifying exposure during primary 
production, there is a need to generate further data on the 
downstream use of nanoparticles and on consequences 
for consumers and the environment. 
4.2.2 Release processes
Exposure to nanoparticles during manufacturing and use 
(including disposal and recycling) depends on particle 
size distribution and other material characteristics (see 
Chapter 3 for further discussion). Besides the usual 
parameters such as geometry and flow rate, net release 
is influenced by agglomeration and other forms of loss. 
Future research will hence need to establish what factors – 
nanomaterial attributes or operational conditions or their 
combination – are the principal determinants of release 
in a range of settings to allow minimising emission and 
control possible exposure. 
4.2.3 Routes of entry and modelling exposure
Most research has focused on the inhalation route, 
examining airborne particles. Much more research 
to evaluate dermal and especially ingestion routes is 
necessary, and this requires development of appropriate 
methods to quantify exposure.
There is often poor correlation when data from models 
for inhalation exposure are compared with real-life 
measurements. The existing models describing exposure 
to nanoparticles are inadequate in incorporating 
nanospecific features such as agglomeration. Similar 
problems are likely to arise in attempting to develop 
validated models for other routes of exposure. Progress 
in modelling requires much more detailed analysis of the 
factors that influence routes of nanoparticle disposition 
such as agglomeration and aggregation.
Given the current state of knowledge about exposure 
to nanomaterials, it is likely that in the short term it will 
be necessary to continue to rely on precautionary risk 
management measures. In the longer term, if the gaps 
can begin to be filled by detailed, harmonised or even 
standardised research approaches then more specific 
risk assessments can be anticipated, as described in the 
NANEX report. This certainly requires better funded and 
well co-ordinated approaches.
4.3 Transfer of knowledge to practice
The outputs from the various research studies described 
in the previous sections are vitally important for multiple 
purposes: (1) for developing, refining, standardising and 
harmonising methods of safety assessment; (2) for the 
definition of objectives for engineers and manufacturers 
in designing safety; and (3) for the formulation of 
regulatory safety guidelines and legislation. Feedback 
from the users of this research knowledge will also be 
115 Nel, A.E. et al., Nature Materials 8, 543 (2009).
116 FP 7 Project Nanex: www.nanex-project.eu.
117 Schmid, K. et al., Journal of Occupational and Environmental Hygiene 7, 224 (2010); Methner, M. et al., Journal of Occupational and 
 Environmental Hygiene 7, 163 (2010).
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crucial in suggesting new directions for research and new 
opportunities to build multidisciplinarity. 
We note that the research communities across 
nanomedicine, nanoengineering and nanosafety are not 
always well linked. We suggest to the research funding 
and higher education bodies that cross-talk should 
be encouraged in addition to the teaching of basic 
understanding about related fields. 
Among the translation gaps that need to be filled for 
the multiple transfers of knowledge into practice are the 
following.
4.3.1 Harmonisation and standardisation
The harmonisation of scientific effort is important because 
it allows comparison of results and pooling of data 
between groups. In addition, it facilitates the considerable 
effort involved in transferring laboratory-scale innovative 
science into routine testing schemes appropriate for 
industrial and regulatory processes internationally, such 
as those developed by the OECD (Chapter 2). 
An important initial step is the harmonisation of protocols 
and reporting so that results can be interpreted adequately. 
European harmonisation necessitates better sharing of 
the scientific and technological perspectives from the 
various partners across academia, industry and policy in 
pursuit of agreed, common goals. It would also be helped 
by new incentives for the transfer of knowledge, given 
that such transfer tends to be neglected in most schemes 
for researcher funding and recognition.
4.3.2 Safety-by-design
The early objective in the design of additional safety is 
to provide engineers and manufacturers with robust 
benchmarks for new materials and products. Although 
there is nothing necessarily special about nanomaterials 
in the concept of safety-by-design, the particular 
challenge lies in the many current knowledge gaps and 
the multidisciplinary approaches involved. 
There is considerable uncertainty about which 
characteristics best explain the hazards and exposure 
potential of nanomaterials. Nonetheless, progress is being 
made. While a refined risk assessment and safe design 
approach may not yet be possible, there are already 
simplified toolkits available for evaluating nanospecific 
risks, compatible with the precautionary approach 
reflected in REACH regulation (see Chapter 2 for further 
details).
4.3.3 Early attention to safety in research
A recent survey118 disclosed that many nanoscientists are 
unaware of safety measures in their own laboratories. 
Consequently, more effort is highly desirable to ensure 
the safety not only of workers during manufacturing and 
downstream use but also of researchers in laboratories. 
The introduction of a code of conduct for researchers 
(Chapter 2) should be helpful in raising awareness 
and improving working practices: we suggest that the 
European Commission should continue to encourage 
use of this code of conduct and monitor the impact of 
implementation. Although very valuable in the research 
environment, a voluntary code may have increasing 
limitations during subsequent product development 
steps where a formalised system of sector-specific 
regulation needs to be applied, as described elsewhere in 
this report.
In the experience of our working group participants, there 
has been a large global increase in research spending in 
both the public and private sectors on health and safety 
aspects relative to nanomaterials119. However, there is room 
to do more to integrate safety objectives into research. 
For example, the Austrian NanoInitiative120 conducts 
a dual review of submitted research proposals, for the 
engineering elements and for the adequacy of health, 
safety and environmental measures. This approach can 
be commended for wider application because it requires 
safety issues to be discussed at an early stage when the 
project still has the greatest flexibility to change. 
We suggest that integration of safety assessment into 
projects dealing with the discovery and development of 
new materials might build on the relevant model from 
the pharmaceutical sector, where hazards and risks are 
customarily addressed at an early stage in research.
4.3.4 Research, regulation and public engagement
As discussed in Chapters 1 and 2, we recommend that 
the European Commission together with the scientific 
community strengthen efforts to define a common 
terminology and common criteria for data collection 
for safety endpoints. We also advise that there is a 
corresponding collective responsibility for policy-makers 
and researchers to provide accurate and accessible 
information to the public about nanomaterials. 
118 Balas F. et al., Nature Nanotechnology 5, 93 (2010).
119 Riediker M. and Katalagarianakis, G. (Eds.), ‘Compendium of Projects in the European NanoSafety Cluster’, Lausanne, Switzerland: 
 Institute for Work and Health, 2010.
120 Austrian Nano Forum: www.nanoinitiative.at.
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Various national activities have shared scientific findings 
with the general public, for example, the UK Royal 
Society dialogue121, the TA-Swiss PubliFocus122, German 
NanoCare81 and French nanodebate123. 
These initiatives demonstrated consistently that the public 
are interested in the topic once they are informed. There 
have also been attempts to involve non-governmental 
organisations associated with environmental and 
consumer protection in stakeholder discussion, for 
example in NanoImpactNet124 and the Swiss Action Plan 
on Nanotechnology (Chapter 2). 
The Framework Programme 7 project Framingnano125 
explored issues with non-governmental organisations for 
the governance of risks and might provide one model for 
discussing future challenges. Although the Framework 
Programme 7 project Nanomedicine Round Table126 
reported patients as uncertain whether nanomedicine 
raises specific safety concerns, they did not view it as 
inherently unsafe. This project called for better co-
ordination and harmonisation of existing regulatory 
procedures, to facilitate data collection and improve 
regulatory clarity, a recommendation that we endorse. 
A particular priority was seen to be the clarification of the 
regulatory pathways for ‘combination products’ which 
may span medical, food and cosmetic product sectors.
In the recent Eurobarometer survey on biotechnology127, 
only 45% of Europeans say that they have heard of 
nanotechnology, described in the survey in the context of 
consumer products. Sixty per cent of those who expressed 
an opinion support such applications of nanotechnology. 
Safety is identified as the main concern, but those who 
are most actively interested in nanotechnology tend to be 
much more inclined to perceive it as safe and beneficial 
compared with those for whom nanotechnology is 
unfamiliar, reinforcing the importance of additional effort 
to communicate and inform. 
4.4 Professional education and training
Generally, there are too few European universities 
offering training in toxicology and in occupational 
and environmental health and safety. Without wider 
commitment to safety science, it will be difficult to develop 
expertise in specialised areas. In terms of nanospecific 
training, the priorities include the following:
Training of researchers in hazard exposure and risk 
assessment to understand what may be distinctive 
about the nanoscale. Such training could be 
included as modules within EU and other research 
programmes.
Training of scientists and engineers developing 
new nanomaterials and production technologies, to 
incorporate safety into design.
Joint training on interdisciplinary collaboration for 
all: researchers, material scientists and production 
engineers. One particularly interesting example of 
such training is the new TWIN Institute in Tokyo, a 
merger between the Engineering School at Waseda 
University and the Medical School at Tokyo Women’s 
Medical University, with emphasis on both basis and 
applied research relevant to nanobiotechnology 
training.
Examples of current European programmes are described 
in Box 4.1 and we suggest that these can serve as models 
for future expansion of training.
121 The Royal Society and The Royal Academy of Engineering, ‘Nanoscience and nanotechnologies: opportunities and uncertainties’, London, 2004.
122 TA-Swiss: www.ta-swiss.ch/en/publifocus-nanotechnology.
123 http://www/developpement-durable.gouv.fr.
124 FP 7 NanoimpactNet Project: www.nanoimpactnet.eu.
125 FP 7 Framingnano Project: www.framingnano.eu.
126 FP 7 Nanomedicine Round Table Project: www.nanomedroundtable.org.
127 Gaskell G. et al., European Commission, EUR 24537 EN (2010).
128 FP7 QNano Research Infrastructure Project: www.qnano-ri.eu.
129 University of Salzburg: www.uni-salzburg.at.
Box 4.1
Examples of current training initiatives
MSc level: QNano128 infrastructure, knowledge and 
training hub builds on foundations laid by NanoIm-
pactNet and uses expertise of established groups in 
toxicology, modelling, nanobiology, occupational ex-
posure and ethics. It will function as virtual training 
for users of European infrastructure and includes a 
repository of lifelong learning materials and expert 
panel resource to tackle educational outreach issues. 
Several national and regional Master’s initiatives (for 
example NanoConnect Scandinavia, a joint venture 
between Universities of Copenhagen, Denmark, and 
Lund, Sweden) in nanoscience and nanotechnolo-
gy also provide models for adoption more widely.
PhD level: One major example is the EU Marie Curie 
training programme NanoTOES (Nanotechnology: 
Training of Experts in Safety129), which provides inter-
disciplinary training to both students and experien-
ced researchers in a network of projects associated 
with the refinement and standardisation of existing 
methods and development of new assays for analy-
sing the biological effects of nanomaterials. Training 
in communication, verification and practical applica-
tion of results are important parts of the programme 
and the highly interdisciplinary objectives are a good 
model for future European PhD training schemes.
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We are convinced that the development of new 
generations of nanomaterials requires a new generation 
of interdisciplinary scientists. 
New training initiatives are essential to confer the 
interdisciplinarity and other attributes that will secure the 
future of nanosafety.
4.5 Summary of main messages
Our main recommendations from this Chapter on ‘Filling 
the Gaps’ are as follows:
The necessary basic and translational (transfer from 
basic science to application) research framework 
encompasses the development of innovative 
methodologies to assess nanospecific hazards, 
validated biological models (in vitro and in vivo), and 
use of meta-analysis and modelling techniques to 
maximise the value of the information gained.
Particular research priorities, using well-characterised 
materials, include better definition of relevant dose–
response relationships, exploration of effects at the 
cellular level, individual organ level and organ–organ 
interaction, and on the immune system.
The scope of exposure science must be clarified 
according to the key issues appertaining for 
nanomaterial primary producers, downstream 
users, consumers and the environment. Current 
priorities include evaluation of the determinants 
of nanomaterial release processes, comprehensive 
assessment of all major biological routes of exposure, 
and the modelling of alternative exposure scenarios.
Transfer of knowledge to practice requires new 
efforts in harmonisation and standardisation of 
methodologies; sharing best practice on attributes for 
safety-by-design; raising awareness of safety issues in 
the research setting as well as in manufacturing, with 
implementation of codes of conduct; and ensuring 
connectivity between the research and regulatory 
communities.
Researchers and policy-makers can benefit from 
working together to support public information 
and engagement, capitalising on recent findings 
indicating that more knowledgeable consumers are 
more confident about nanosafety.
New initiatives in nanospecific training at Master’s and 
PhD levels are important to support interdisciplinarity 
and to provide the next generation of researchers 
with the skills to assess the next generations of 
nanomaterials.
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5 Conclusions
Our Working Group discussions confirmed that 
the regulatory framework for safety assessment of 
nanomaterials should adopt the same principles and 
sector-specific requirements applied in other product 
development. A clear scientific and regulatory framework 
to address potential health and environmental impacts 
of nanomaterials must be central to Europe’s integrated 
efforts in nanotechnology innovation. Even if many 
areas of nanotechnology do not create new hazards, it is 
important to evaluate whether new forms of engineered 
nanomaterials may require modification of existing 
regulations.
A recent publication from policy-makers in the European 
Commission, OECD and US Environmental Protection 
Agency130 emphasised a continuing requirement for high-
quality data on the toxicology of nanomaterials, both to 
support specific regulatory decisions and to generate the 
wider knowledge base needed to determine how data 
can be extrapolated for other nanomaterials that have 
not been studied to the same level of detail. Current test 
methods must be optimised and standardised while also 
evaluating alternative testing strategies and providing 
robust measurements of exposure. Given the magnitude 
of the task, there is also the need for screening approaches 
that inform decision makers how to set priorities for 
testing in more depth of different nanomaterials. 
This is consistent with the issues identified, and 
recommendations offered, in the preceding chapters of 
our report. We propose the following:
Regulators and researchers should work together in 
identifying priorities for gaining new knowledge.
Scientifically sound approaches should be used 
for managing nanomaterial risks in the absence of 
sufficient specific data.
Opportunities to minimise risk by ‘safety-by-design’ 
(Chapter 4) can be identified before nanomaterials 
enter into use.
The recent review by the policy-makers also observed 
that the first widely read report to evaluate the benefits 
and risks of nanotechnology was published by the Royal 
Society and the Royal Academy of Engineering in 2004 
(see footnote 121). As generation of new knowledge must 
keep pace with the future development of nanomaterials, 
the Academies of Science from across Europe, together 
with the JRC, have aimed to extend that earlier analysis 
and interpretation to reduce the many uncertainties 
about the potential impacts of nanomaterials on health, 
safety and the environment. 
We advise that it is important to do the following:
Use as precise as possible a definition of what is 
meant by nanomaterials: researchers and regulators 
may need to develop a more differentiated approach 
to assessment and regulation131.
Distinguish between embedded and free 
nanomaterials (while also recognising that the status 
of the nanomaterial may vary during its lifecycle) as 
part of any differentiated risk assessment. 
Differentiate more precisely between the unintended 
exposure to environmental nanoscale particles from 
combustion or other natural processes, and the 
unintended and intended exposure to engineered 
nanomaterials.
Build on the increasingly well understood principles 
and standards that are now part of the broader 
field of toxicology, in consequence of advances in 
other areas, for example in the safety assessment of 
chemicals and pharmaceuticals.
Recommendations for the responsible development 
of nanomaterials
Specific recommendations have been discussed in the 
previous chapters, where we have tried to clarify ‘what we 
currently know’ and ‘what we need to know’. 
The improved assessment of the potential risks of 
engineered nanomaterials requires significant effort 
to promote, extend and co-ordinate basic and applied 
research, and to translate research outputs into products 
and into informed policy decisions. A coherent, well-
orchestrated strategy for the EU must be multidisciplinary 
and multi-sectoral, requiring new efforts in data collection, 
new infrastructure and new training, involving academia, 
industry, policy-makers and other stakeholders.
New knowledge on safety assessment must be considered 
within the overall objective of establishing the benefit–risk 
balance. In this context, we identify three key messages: 
Safety research is an essential part of the innovation 
of nanomaterials (‘safety-by-design’ principle).
Research governance and product regulation 
must be sufficiently flexible to cope with future 
developments.
130 Morris, J. et al., Nature Nanotechnology 6, 73 (2011).
131 Drezek, R.A. and Tour, J.M., Nature Nanotechnology 5, 168 (2010).
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Inappropriate or over-regulation can act as an 
obstacle to fundamental research and its translation 
into products which, when used in a safe manner, can 
contribute to justified societal objectives.
Some of the key action areas to be addressed in order to 
improve understanding of the current applications and 
prepare for future applications of nanomaterials are as 
follows:
Research capacity. Increasing volume and quality of 
research on safety aspects are required to progress 
further standardisation of methods; to widen 
laboratory networks across the EU and beyond; to 
build upon existing and develop new centres of 
excellence, avoiding unnecessary duplication; and 
to promote linkage between disciplines. We advise 
that it is essential to use well-characterised materials, 
to study chronic as well as acute effects, to assess 
toxicokinetics in systemic studies and to use realistic 
dose levels, considering exposure throughout the 
nanomaterial’s lifecycle.
Training capacity. Support for younger scientists 
– and the European Commission has a pivotal role 
in its funding programmes – is greatly needed. 
Multidisciplinary training and integrated teaching of 
nanotechnology at all levels from undergraduate to 
post-doctoral have to be introduced.
Research governance and integrity. Awareness and 
responsibility have to be developed at the individual, 
research institution and company levels, building on 
current codes of conduct while exploring the options 
for other governance frameworks.
Product regulation. Generally, the approval of novel 
products emanating from nanotechnology should be 
subject to the same regulatory principles and practices 
as exist for products derived from other sources. As in 
other regulation, there are issues to be considered for 
cost–benefit balance as well as risk–benefit balance. 
Product regulation should include consideration 
of the issues, where appropriate, for sustainable 
disposal, degradation and recycling of engineered 
nanomaterials. Approaches to product regulation 
and to research governance within the EU should 
be integrated, where possible, with international 
initiatives to ensure complementarity and minimise 
duplication of effort; further duplication should be 
avoided by assigning responsibility to specialist 
national or European institutions; to offer test 
certificates to companies producing nanomaterials 
or consumer products containing them.
Societal engagement. Scientific and policy-making 
communities must work together in providing 
accurate and relevant information to support public 
dialogue on hopes and concerns and to address 
alarmist assertions that sometimes appear in media 
reports of nanotechnology. This dialogue should 
include ethical as well as legal issues. The rapid 
advances in technology present challenges both for 
policy-makers and for public understanding and will 
induce many uncertainties. A recent EASAC report132 
discusses in further detail some of these issues for 
synthetic biology as an emerging technology and 
the recommendations in that report for public 
engagement are also relevant for nanomaterials. 
Common terminology and consensus definition of 
nanomaterials should be developed for effective 
public engagement, as well as for the objectives 
of standardising research methodologies and 
developing an optimised regulatory framework.
EU competitiveness. Nanotechnology has the 
potential to play a major role in European innovation 
and economic growth. There are significant 
implications for small and large companies.
Worldwide harmonisation. Ethical, legal and societal 
issues as well as environmental, health and safety 
issues of nanomaterials allow the building of bridges 
beside the worldwide competitiveness. This facilitates 
worldwide trade, with significant implications for 
business.
In conclusion, the scientific community has a continuing 
responsibility to advise the European Commission and 
European Parliament about the opportunities now 
coming within range. It is often difficult to estimate the 
timeframe for the development of specific engineered 
nanomaterials and their launch as novel products. 
Therefore, it is vitally important to create the appropriate 
supportive environment for innovation and flexibility 
in risk management (e.g. mandatory product register, 
labelling) to prepare for the envisaged longer term as 
well as for the shorter term encompassing the current 
and next generation of products. To this end, it is essential 
to invest in the science of safety assessment while, at the 
same time, seeking to expedite the regulatory review of 
the products emerging from that science. The stringency 
of the controls should match the potential of exposure.
We reiterate that there is only a limited amount of scientific 
evidence to suggest that nanomaterials present a risk 
for human health and we advise that the principles of 
risk assessment procedures should conform to the same 
procedures as any other new material, paying due respect 
to new phenomena that may occur due to new properties 
related to the nanoscale. Successful innovation, if it is to 
encompass both regulatory and consumer approval, must 
incorporate safety by design.
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6.1 List of abbreviations
CA   Competent Authority
CASG Nano  Competent Authorities Sub Group on Nanomaterials (REACH)
CEN   European Committee for Standardisation
DEFRA    Department for Environment, Food and Rural Affairs (UK)
DNA   Deoxyribonucleic acid
EASAC   European Academies Science Advisory Council
EC   European Commission
ECETOC   European Centre for Ecotoxicology and Toxicology of Chemicals 
EFSA   European Food Safety Authority
EHS   European Health and Safety
EPA   Environmental Protection Agency (USA)
EU   European Union
FP7   Seventh Framework Programme
ISO   International Organisation for Standardisation
JRC   Joint Research Centre
JWG   Joint Working Group
MSc   Master of science
NanoTOES  Nanotechnology: Training of Experts Safety
NT   Nanotechnology
OECD   Organisation for Economic Co-operation and Development
PM   Particulate matter
REACH   Registration, Evaluation, Authorisation and Restriction of Chemicals 
SCCP   Scientific Committee on Consumer Products
SCENIHR  Scientific Committee on Emerging and Newly Identified Health Risks
STOA   Science and Technology Options Assessment (European Parliament)
TC   Technical Committee
TSCA   Toxic Substances Control Act
WG   Working Group
WPMN   Working Party on Manufactured Nanomaterials
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